Stem definition | Drug id | CAS RN |
---|---|---|
immunosuppressants, rapamycin derivatives | 1118 | 159351-69-6 |
Dose | Unit | Route |
---|---|---|
10 | mg | O |
1.50 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.01 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.15 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 22, 2019 | PMDA | Novartis Pharma K.K. | |
Sept. 2, 2011 | EMA | ||
March 30, 2009 | FDA | NOVARTIS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Malignant neoplasm progression | 3310.08 | 12.72 | 1620 | 59478 | 66504 | 50477522 |
Stomatitis | 1488.17 | 12.72 | 1119 | 59979 | 100225 | 50443801 |
Metastases to liver | 1053.95 | 12.72 | 505 | 60593 | 19599 | 50524427 |
Metastases to bone | 1029.18 | 12.72 | 480 | 60618 | 17515 | 50526511 |
Pneumonitis | 933.08 | 12.72 | 528 | 60570 | 28982 | 50515044 |
Neoplasm progression | 538.86 | 12.72 | 371 | 60727 | 28786 | 50515240 |
Metastases to lung | 433.48 | 12.72 | 228 | 60870 | 10792 | 50533234 |
Disease progression | 342.71 | 12.72 | 496 | 60602 | 95370 | 50448656 |
Mucosal inflammation | 340.65 | 12.72 | 324 | 60774 | 39818 | 50504208 |
Death | 323.65 | 12.72 | 993 | 60105 | 324386 | 50219640 |
Pleural effusion | 323.08 | 12.72 | 443 | 60655 | 81011 | 50463015 |
Tumour marker increased | 294.86 | 12.72 | 126 | 60972 | 3714 | 50540312 |
Metastases to lymph nodes | 258.36 | 12.72 | 139 | 60959 | 6885 | 50537141 |
Hyperglycaemia | 257.26 | 12.72 | 266 | 60832 | 36139 | 50507887 |
Rheumatoid arthritis | 224.57 | 12.72 | 4 | 61094 | 202546 | 50341480 |
Interstitial lung disease | 210.39 | 12.72 | 289 | 60809 | 52887 | 50491139 |
Osteonecrosis of jaw | 198.63 | 12.72 | 220 | 60878 | 32306 | 50511720 |
Aphthous ulcer | 198.38 | 12.72 | 136 | 60962 | 10461 | 50533565 |
Ascites | 197.68 | 12.72 | 230 | 60868 | 35631 | 50508395 |
Decreased appetite | 190.64 | 12.72 | 604 | 60494 | 200319 | 50343707 |
Drug ineffective | 177.01 | 12.72 | 463 | 60635 | 818870 | 49725156 |
Cough | 167.32 | 12.72 | 654 | 60444 | 240610 | 50303416 |
Infusion related reaction | 158.98 | 12.72 | 12 | 61086 | 169545 | 50374481 |
Breast cancer metastatic | 157.15 | 12.72 | 117 | 60981 | 10247 | 50533779 |
Arthropathy | 148.53 | 12.72 | 11 | 61087 | 157895 | 50386131 |
PIK3CA-activated mutation | 147.71 | 12.72 | 50 | 61048 | 760 | 50543266 |
Systemic lupus erythematosus | 147.38 | 12.72 | 5 | 61093 | 140617 | 50403409 |
Metastases to pleura | 145.52 | 12.72 | 56 | 61042 | 1250 | 50542776 |
Completed suicide | 144.52 | 12.72 | 3 | 61095 | 131886 | 50412140 |
Condition aggravated | 142.07 | 12.72 | 92 | 61006 | 296966 | 50247060 |
Hepatic lesion | 138.19 | 12.72 | 76 | 61022 | 3932 | 50540094 |
General physical health deterioration | 137.52 | 12.72 | 431 | 60667 | 142003 | 50402023 |
Metastases to skin | 135.41 | 12.72 | 54 | 61044 | 1329 | 50542697 |
Oral pain | 135.34 | 12.72 | 159 | 60939 | 24874 | 50519152 |
Synovitis | 135.00 | 12.72 | 3 | 61095 | 123862 | 50420164 |
Exposure during pregnancy | 131.62 | 12.72 | 3 | 61095 | 121012 | 50423014 |
Musculoskeletal stiffness | 129.79 | 12.72 | 6 | 61092 | 128475 | 50415551 |
Therapeutic product effect decreased | 126.47 | 12.72 | 10 | 61088 | 136040 | 50407986 |
Lung disorder | 125.10 | 12.72 | 207 | 60891 | 44592 | 50499434 |
Drug hypersensitivity | 119.61 | 12.72 | 78 | 61020 | 250932 | 50293094 |
Neoplasm malignant | 117.34 | 12.72 | 144 | 60954 | 23571 | 50520455 |
Maternal exposure during pregnancy | 117.06 | 12.72 | 25 | 61073 | 159753 | 50384273 |
Metastases to peritoneum | 112.46 | 12.72 | 59 | 61039 | 2774 | 50541252 |
Second primary malignancy | 111.46 | 12.72 | 81 | 61017 | 6833 | 50537193 |
Metastasis | 111.07 | 12.72 | 68 | 61030 | 4307 | 50539719 |
Mouth ulceration | 108.81 | 12.72 | 151 | 60947 | 27873 | 50516153 |
Epistaxis | 106.21 | 12.72 | 237 | 60861 | 63717 | 50480309 |
Fall | 106.15 | 12.72 | 150 | 60948 | 334782 | 50209244 |
Lung infiltration | 102.10 | 12.72 | 102 | 60996 | 13291 | 50530735 |
Joint swelling | 100.50 | 12.72 | 89 | 61009 | 245197 | 50298829 |
Blood creatinine increased | 99.32 | 12.72 | 257 | 60841 | 75903 | 50468123 |
Polyomavirus viraemia | 97.88 | 12.72 | 32 | 61066 | 434 | 50543592 |
Pyrexia | 97.20 | 12.72 | 787 | 60311 | 379416 | 50164610 |
Metastases to spine | 95.72 | 12.72 | 53 | 61045 | 2778 | 50541248 |
Oedema peripheral | 95.69 | 12.72 | 411 | 60687 | 157550 | 50386476 |
Lymphangiosis carcinomatosa | 91.01 | 12.72 | 39 | 61059 | 1157 | 50542869 |
Metastases to central nervous system | 89.85 | 12.72 | 88 | 61010 | 11194 | 50532832 |
Dysgeusia | 88.10 | 12.72 | 164 | 60934 | 38752 | 50505274 |
Hypersensitivity | 84.64 | 12.72 | 81 | 61017 | 215080 | 50328946 |
Acne | 84.31 | 12.72 | 111 | 60987 | 19484 | 50524542 |
Blood triglycerides increased | 84.11 | 12.72 | 85 | 61013 | 11227 | 50532799 |
Blood glucose increased | 82.24 | 12.72 | 230 | 60868 | 71094 | 50472932 |
Diarrhoea | 80.93 | 12.72 | 1073 | 60025 | 587403 | 49956623 |
Infusion site coldness | 80.51 | 12.72 | 23 | 61075 | 191 | 50543835 |
Lymphoedema | 79.93 | 12.72 | 75 | 61023 | 9047 | 50534979 |
Carbohydrate antigen 15-3 increased | 79.88 | 12.72 | 35 | 61063 | 1097 | 50542929 |
Gamma-glutamyltransferase increased | 78.84 | 12.72 | 134 | 60964 | 29489 | 50514537 |
Blood lactate dehydrogenase increased | 76.83 | 12.72 | 106 | 60992 | 19456 | 50524570 |
Transplant rejection | 76.61 | 12.72 | 75 | 61023 | 9534 | 50534492 |
BK virus infection | 76.27 | 12.72 | 46 | 61052 | 2835 | 50541191 |
Gamma-glutamyltransferase decreased | 76.16 | 12.72 | 24 | 61074 | 287 | 50543739 |
Sinusitis | 73.35 | 12.72 | 59 | 61039 | 170499 | 50373527 |
Weight decreased | 72.99 | 12.72 | 487 | 60611 | 220758 | 50323268 |
Anaemia | 72.94 | 12.72 | 538 | 60560 | 251918 | 50292108 |
Discomfort | 71.53 | 12.72 | 21 | 61077 | 108359 | 50435667 |
Product use in unapproved indication | 71.36 | 12.72 | 303 | 60795 | 115516 | 50428510 |
Treatment failure | 70.78 | 12.72 | 39 | 61059 | 137598 | 50406428 |
Wound | 70.74 | 12.72 | 20 | 61078 | 105774 | 50438252 |
Weight increased | 70.47 | 12.72 | 84 | 61014 | 201807 | 50342219 |
Hypertriglyceridaemia | 70.14 | 12.72 | 56 | 61042 | 5435 | 50538591 |
Off label use | 69.99 | 12.72 | 315 | 60783 | 474111 | 50069915 |
Pericarditis | 69.81 | 12.72 | 7 | 61091 | 78682 | 50465344 |
Bone lesion | 68.78 | 12.72 | 54 | 61044 | 5116 | 50538910 |
Immunosuppressant drug level increased | 68.42 | 12.72 | 44 | 61054 | 3038 | 50540988 |
Blood chromogranin A increased | 68.15 | 12.72 | 21 | 61077 | 232 | 50543794 |
Arthralgia | 67.29 | 12.72 | 287 | 60811 | 438415 | 50105611 |
Hypophosphataemia | 63.98 | 12.72 | 64 | 61034 | 8350 | 50535676 |
Concomitant disease progression | 62.95 | 12.72 | 36 | 61062 | 2009 | 50542017 |
Pericardial effusion | 60.63 | 12.72 | 110 | 60988 | 25479 | 50518547 |
Product dose omission issue | 60.49 | 12.72 | 80 | 61018 | 183758 | 50360268 |
Pain | 60.16 | 12.72 | 431 | 60667 | 578472 | 49965554 |
Therapeutic product effect incomplete | 59.90 | 12.72 | 18 | 61080 | 91497 | 50452529 |
Thrombotic microangiopathy | 59.84 | 12.72 | 63 | 61035 | 8728 | 50535298 |
Drug abuse | 59.75 | 12.72 | 3 | 61095 | 59843 | 50484183 |
Diabetes mellitus | 59.36 | 12.72 | 161 | 60937 | 48872 | 50495154 |
Dyspnoea | 58.42 | 12.72 | 956 | 60142 | 546652 | 49997374 |
Kidney transplant rejection | 58.19 | 12.72 | 44 | 61054 | 3943 | 50540083 |
Bone pain | 58.10 | 12.72 | 156 | 60942 | 47073 | 50496953 |
Nail disorder | 56.38 | 12.72 | 64 | 61034 | 9644 | 50534382 |
Therapy cessation | 55.62 | 12.72 | 107 | 60991 | 25904 | 50518122 |
Renal impairment | 55.44 | 12.72 | 209 | 60889 | 75452 | 50468574 |
Thrombocytopenia | 55.43 | 12.72 | 302 | 60796 | 127371 | 50416655 |
Cell marker increased | 54.34 | 12.72 | 18 | 61080 | 255 | 50543771 |
Loss of personal independence in daily activities | 53.27 | 12.72 | 10 | 61088 | 70040 | 50473986 |
Feeding disorder | 51.77 | 12.72 | 64 | 61034 | 10549 | 50533477 |
Breast cancer recurrent | 51.14 | 12.72 | 40 | 61058 | 3768 | 50540258 |
Abdominal lymphadenopathy | 51.14 | 12.72 | 22 | 61076 | 659 | 50543367 |
Arthritis | 50.02 | 12.72 | 21 | 61077 | 86700 | 50457326 |
Eating disorder | 49.59 | 12.72 | 76 | 61022 | 15333 | 50528693 |
Pancreatic neuroendocrine tumour | 49.47 | 12.72 | 17 | 61081 | 271 | 50543755 |
Somnolence | 49.40 | 12.72 | 69 | 61029 | 154916 | 50389110 |
Overdose | 48.78 | 12.72 | 30 | 61068 | 99697 | 50444329 |
Device related thrombosis | 48.43 | 12.72 | 26 | 61072 | 1281 | 50542745 |
Palmar-plantar erythrodysaesthesia syndrome | 48.38 | 12.72 | 87 | 61011 | 20011 | 50524015 |
Hypotension | 48.19 | 12.72 | 136 | 60962 | 235333 | 50308693 |
Helicobacter infection | 48.05 | 12.72 | 3 | 61095 | 49699 | 50494327 |
Metastases to chest wall | 47.97 | 12.72 | 19 | 61079 | 459 | 50543567 |
Suicide attempt | 47.49 | 12.72 | 4 | 61094 | 51728 | 50492298 |
Lower respiratory tract infection | 47.46 | 12.72 | 28 | 61070 | 95173 | 50448853 |
Bradycardia | 47.31 | 12.72 | 10 | 61088 | 64416 | 50479610 |
Glossodynia | 47.18 | 12.72 | 42 | 61056 | 115527 | 50428499 |
Irritable bowel syndrome | 47.17 | 12.72 | 4 | 61094 | 51437 | 50492589 |
Mobility decreased | 46.69 | 12.72 | 19 | 61079 | 79929 | 50464097 |
Lymphadenopathy mediastinal | 46.45 | 12.72 | 32 | 61066 | 2479 | 50541547 |
Infusion site induration | 45.90 | 12.72 | 22 | 61076 | 851 | 50543175 |
Liver transplant rejection | 45.60 | 12.72 | 25 | 61073 | 1285 | 50542741 |
Intentional product use issue | 45.38 | 12.72 | 18 | 61080 | 76900 | 50467126 |
Drug intolerance | 45.24 | 12.72 | 126 | 60972 | 218978 | 50325048 |
West Nile viral infection | 44.92 | 12.72 | 17 | 61081 | 362 | 50543664 |
Spinal pain | 44.63 | 12.72 | 60 | 61038 | 10743 | 50533283 |
Viraemia | 44.42 | 12.72 | 23 | 61075 | 1052 | 50542974 |
Oncologic complication | 44.38 | 12.72 | 13 | 61085 | 119 | 50543907 |
Polyomavirus-associated nephropathy | 44.26 | 12.72 | 26 | 61072 | 1526 | 50542500 |
Hormone receptor positive breast cancer | 44.21 | 12.72 | 18 | 61080 | 468 | 50543558 |
Parvovirus B19 infection | 44.18 | 12.72 | 18 | 61080 | 469 | 50543557 |
Concomitant disease aggravated | 43.07 | 12.72 | 51 | 61047 | 8040 | 50535986 |
Mean cell haemoglobin decreased | 42.68 | 12.72 | 34 | 61064 | 3289 | 50540737 |
Product use issue | 42.41 | 12.72 | 72 | 61026 | 149403 | 50394623 |
Needle issue | 42.32 | 12.72 | 48 | 61050 | 7227 | 50536799 |
Alopecia | 42.13 | 12.72 | 153 | 60945 | 244894 | 50299132 |
Malignant pleural effusion | 41.48 | 12.72 | 29 | 61069 | 2301 | 50541725 |
Metastases to the mediastinum | 41.37 | 12.72 | 17 | 61081 | 453 | 50543573 |
Suicidal ideation | 39.85 | 12.72 | 9 | 61089 | 55376 | 50488650 |
Depression | 39.70 | 12.72 | 88 | 61010 | 165335 | 50378691 |
Pancreatic neuroendocrine tumour metastatic | 39.29 | 12.72 | 8 | 61090 | 10 | 50544016 |
Karnofsky scale worsened | 39.29 | 12.72 | 8 | 61090 | 10 | 50544016 |
Polyneuropathy | 39.27 | 12.72 | 60 | 61038 | 12071 | 50531955 |
Injection site pain | 38.91 | 12.72 | 46 | 61052 | 110978 | 50433048 |
Cholangitis | 38.87 | 12.72 | 37 | 61061 | 4542 | 50539484 |
Fatigue | 38.45 | 12.72 | 1121 | 59977 | 706480 | 49837546 |
Blood cholesterol increased | 38.37 | 12.72 | 150 | 60948 | 55065 | 50488961 |
Injection site reaction | 38.34 | 12.72 | 7 | 61091 | 50025 | 50494001 |
Renal tubular necrosis | 38.28 | 12.72 | 54 | 61044 | 10114 | 50533912 |
Body temperature decreased | 38.23 | 12.72 | 70 | 61028 | 16325 | 50527701 |
Cachexia | 37.29 | 12.72 | 36 | 61062 | 4497 | 50539529 |
Abdominal discomfort | 36.99 | 12.72 | 149 | 60949 | 231492 | 50312534 |
Hypercholesterolaemia | 36.65 | 12.72 | 57 | 61041 | 11646 | 50532380 |
Hepatic neoplasm | 36.54 | 12.72 | 24 | 61074 | 1718 | 50542308 |
Pneumocystis jirovecii pneumonia | 35.97 | 12.72 | 64 | 61034 | 14599 | 50529427 |
Carcinoembryonic antigen increased | 35.11 | 12.72 | 22 | 61076 | 1452 | 50542574 |
Toxicity to various agents | 35 | 12.72 | 135 | 60963 | 212364 | 50331662 |
Injection site pruritus | 34.80 | 12.72 | 4 | 61094 | 40407 | 50503619 |
Hyperhidrosis | 34.73 | 12.72 | 34 | 61064 | 89392 | 50454634 |
Drug level decreased | 34.48 | 12.72 | 41 | 61057 | 6492 | 50537534 |
Accidental exposure to product packaging | 34.32 | 12.72 | 6 | 61092 | 0 | 50544026 |
Neoplasm | 34.29 | 12.72 | 39 | 61059 | 5889 | 50538137 |
Unevaluable event | 34.13 | 12.72 | 7 | 61091 | 46059 | 50497967 |
Blood alkaline phosphatase increased | 33.81 | 12.72 | 111 | 60987 | 37415 | 50506611 |
Metastases to thorax | 33.78 | 12.72 | 12 | 61086 | 212 | 50543814 |
Ill-defined disorder | 33.56 | 12.72 | 12 | 61086 | 54642 | 50489384 |
C-reactive protein increased | 33.51 | 12.72 | 164 | 60934 | 66310 | 50477716 |
Swelling | 33.48 | 12.72 | 127 | 60971 | 200745 | 50343281 |
Psoriasis | 33.40 | 12.72 | 21 | 61077 | 68979 | 50475047 |
Anaphylactic reaction | 32.96 | 12.72 | 12 | 61086 | 54043 | 50489983 |
Proteinuria | 32.73 | 12.72 | 66 | 61032 | 16531 | 50527495 |
Post-traumatic neck syndrome | 32.21 | 12.72 | 23 | 61075 | 1887 | 50542139 |
Injection site erythema | 32.09 | 12.72 | 26 | 61072 | 74910 | 50469116 |
Skin toxicity | 32.05 | 12.72 | 31 | 61067 | 3882 | 50540144 |
Complications of transplanted kidney | 31.75 | 12.72 | 24 | 61074 | 2149 | 50541877 |
Headache | 31.45 | 12.72 | 427 | 60671 | 506108 | 50037918 |
Balance disorder | 30.84 | 12.72 | 24 | 61074 | 70566 | 50473460 |
Metastases to muscle | 30.76 | 12.72 | 10 | 61088 | 133 | 50543893 |
Dehydration | 30.73 | 12.72 | 300 | 60798 | 152149 | 50391877 |
Chronic obstructive pulmonary disease | 30.71 | 12.72 | 13 | 61085 | 53422 | 50490604 |
Haemoglobin decreased | 30.54 | 12.72 | 260 | 60838 | 126956 | 50417070 |
Pseudocirrhosis | 30.49 | 12.72 | 15 | 61083 | 615 | 50543411 |
Osteoarthritis | 30.39 | 12.72 | 23 | 61075 | 68583 | 50475443 |
Glomerular filtration rate decreased | 30.06 | 12.72 | 52 | 61046 | 11600 | 50532426 |
Hepatic enzyme increased | 29.84 | 12.72 | 77 | 61021 | 137303 | 50406723 |
Adverse event | 29.75 | 12.72 | 8 | 61090 | 43755 | 50500271 |
Onychoclasis | 29.74 | 12.72 | 34 | 61064 | 5162 | 50538864 |
Pleural neoplasm | 29.25 | 12.72 | 11 | 61087 | 230 | 50543796 |
Asthenia | 29.19 | 12.72 | 544 | 60554 | 318498 | 50225528 |
Neuroendocrine tumour | 29.15 | 12.72 | 14 | 61084 | 544 | 50543482 |
Metastases to adrenals | 29.11 | 12.72 | 15 | 61083 | 679 | 50543347 |
Agitation | 29.10 | 12.72 | 14 | 61084 | 53370 | 50490656 |
Bone cancer | 28.99 | 12.72 | 18 | 61080 | 1169 | 50542857 |
Cardiac arrest | 28.94 | 12.72 | 35 | 61063 | 83616 | 50460410 |
Nephrotic syndrome | 28.64 | 12.72 | 32 | 61066 | 4738 | 50539288 |
Drug interaction | 27.86 | 12.72 | 135 | 60963 | 199486 | 50344540 |
Metastases to kidney | 27.78 | 12.72 | 10 | 61088 | 184 | 50543842 |
Nephritic syndrome | 27.68 | 12.72 | 10 | 61088 | 186 | 50543840 |
Platelet count decreased | 27.50 | 12.72 | 212 | 60886 | 100514 | 50443512 |
Gait disturbance | 26.86 | 12.72 | 92 | 61006 | 149913 | 50394113 |
Hypophagia | 26.77 | 12.72 | 84 | 61014 | 27644 | 50516382 |
Nasopharyngitis | 26.62 | 12.72 | 131 | 60967 | 192796 | 50351230 |
Vasodilatation | 26.49 | 12.72 | 22 | 61076 | 2257 | 50541769 |
Flatulence | 26.41 | 12.72 | 87 | 61011 | 29371 | 50514655 |
Injury | 26.41 | 12.72 | 13 | 61085 | 48912 | 50495114 |
Gastrointestinal disorder | 26.32 | 12.72 | 46 | 61052 | 94410 | 50449616 |
Abdominal distension | 26.13 | 12.72 | 164 | 60934 | 72739 | 50471287 |
Cardiac failure | 25.98 | 12.72 | 169 | 60929 | 75871 | 50468155 |
Treatment noncompliance | 25.92 | 12.72 | 3 | 61095 | 30147 | 50513879 |
Immunosuppressant drug level decreased | 25.86 | 12.72 | 15 | 61083 | 860 | 50543166 |
Dry skin | 25.79 | 12.72 | 112 | 60986 | 43079 | 50500947 |
Heart transplant rejection | 25.58 | 12.72 | 12 | 61086 | 442 | 50543584 |
Reflux gastritis | 25.57 | 12.72 | 15 | 61083 | 878 | 50543148 |
Breast cancer | 25.45 | 12.72 | 111 | 60987 | 42779 | 50501247 |
Cardio-respiratory arrest | 25.27 | 12.72 | 17 | 61081 | 53875 | 50490151 |
Confusional state | 25.22 | 12.72 | 127 | 60971 | 185801 | 50358225 |
Folliculitis | 25.15 | 12.72 | 8 | 61090 | 39217 | 50504809 |
Myocardial infarction | 25.13 | 12.72 | 43 | 61055 | 88984 | 50455042 |
Metastases to bladder | 24.78 | 12.72 | 9 | 61089 | 170 | 50543856 |
Lymphocele | 24.53 | 12.72 | 14 | 61084 | 778 | 50543248 |
Eastern Cooperative Oncology Group performance status worsened | 24.51 | 12.72 | 13 | 61085 | 625 | 50543401 |
Dizziness | 24.44 | 12.72 | 284 | 60814 | 346085 | 50197941 |
Visual impairment | 24.22 | 12.72 | 28 | 61070 | 68247 | 50475779 |
Cancer pain | 24.07 | 12.72 | 22 | 61076 | 2565 | 50541461 |
Vision blurred | 24.07 | 12.72 | 36 | 61062 | 78611 | 50465415 |
Lymphocyte count decreased | 23.86 | 12.72 | 78 | 61020 | 26229 | 50517797 |
Adverse drug reaction | 23.84 | 12.72 | 19 | 61079 | 55203 | 50488823 |
Cerebrovascular accident | 23.84 | 12.72 | 49 | 61049 | 94631 | 50449395 |
Loss of consciousness | 23.82 | 12.72 | 57 | 61041 | 104296 | 50439730 |
Joint stiffness | 23.75 | 12.72 | 4 | 61094 | 30304 | 50513722 |
Syncope | 23.72 | 12.72 | 56 | 61042 | 102946 | 50441080 |
Blood pressure fluctuation | 23.51 | 12.72 | 7 | 61091 | 35816 | 50508210 |
Carcinoid tumour pulmonary | 23.28 | 12.72 | 11 | 61087 | 412 | 50543614 |
Insulinoma | 23.17 | 12.72 | 7 | 61091 | 72 | 50543954 |
Jejunal ulcer perforation | 22.98 | 12.72 | 6 | 61092 | 34 | 50543992 |
Lactic acidosis | 22.86 | 12.72 | 6 | 61092 | 33349 | 50510677 |
Hallucination | 22.86 | 12.72 | 14 | 61084 | 46643 | 50497383 |
Plasma cell myeloma | 22.71 | 12.72 | 5 | 61093 | 31317 | 50512709 |
Exposed bone in jaw | 22.59 | 12.72 | 22 | 61076 | 2778 | 50541248 |
Cognitive disorder | 21.95 | 12.72 | 13 | 61085 | 44110 | 50499916 |
Metastases to pelvis | 21.66 | 12.72 | 10 | 61088 | 355 | 50543671 |
Therapy change | 21.55 | 12.72 | 29 | 61069 | 5196 | 50538830 |
Lymphangitis | 21.47 | 12.72 | 13 | 61085 | 807 | 50543219 |
Pulmonary tumour thrombotic microangiopathy | 21.31 | 12.72 | 6 | 61092 | 47 | 50543979 |
Infusion site haemorrhage | 21.29 | 12.72 | 22 | 61076 | 2982 | 50541044 |
Pulmonary mass | 21.22 | 12.72 | 60 | 61038 | 18645 | 50525381 |
Abortion spontaneous | 21.22 | 12.72 | 12 | 61086 | 41760 | 50502266 |
Hepatitis E | 21.19 | 12.72 | 15 | 61083 | 1214 | 50542812 |
Blood creatinine decreased | 21.11 | 12.72 | 28 | 61070 | 4948 | 50539078 |
Memory impairment | 20.90 | 12.72 | 40 | 61058 | 79320 | 50464706 |
Hepatic mass | 20.75 | 12.72 | 16 | 61082 | 1476 | 50542550 |
Recurrent cancer | 20.50 | 12.72 | 17 | 61081 | 1740 | 50542286 |
Ageusia | 20.43 | 12.72 | 44 | 61054 | 11539 | 50532487 |
Intestinal metastasis | 20.35 | 12.72 | 7 | 61091 | 112 | 50543914 |
Cornea verticillata | 20.19 | 12.72 | 6 | 61092 | 58 | 50543968 |
Tumour necrosis | 20.16 | 12.72 | 12 | 61086 | 722 | 50543304 |
Lymphadenopathy | 20.10 | 12.72 | 87 | 61011 | 33412 | 50510614 |
Kidney congestion | 20.02 | 12.72 | 5 | 61093 | 23 | 50544003 |
Emotional distress | 19.94 | 12.72 | 5 | 61093 | 28658 | 50515368 |
Post transplant lymphoproliferative disorder | 19.94 | 12.72 | 25 | 61073 | 4179 | 50539847 |
Metastases to spleen | 19.85 | 12.72 | 7 | 61091 | 121 | 50543905 |
Skin sensitisation | 19.73 | 12.72 | 12 | 61086 | 751 | 50543275 |
Blood pressure systolic increased | 19.71 | 12.72 | 90 | 61008 | 35359 | 50508667 |
Urticaria | 19.62 | 12.72 | 85 | 61013 | 129476 | 50414550 |
Cheilitis | 19.62 | 12.72 | 23 | 61075 | 3587 | 50540439 |
Asthma | 19.45 | 12.72 | 50 | 61048 | 89287 | 50454739 |
Angiosarcoma | 19.33 | 12.72 | 8 | 61090 | 217 | 50543809 |
Oral herpes | 19.29 | 12.72 | 62 | 61036 | 20663 | 50523363 |
Peripheral coldness | 19.22 | 12.72 | 40 | 61058 | 10243 | 50533783 |
Tumour marker abnormal | 19.20 | 12.72 | 8 | 61090 | 221 | 50543805 |
Drug level increased | 19.18 | 12.72 | 59 | 61039 | 19209 | 50524817 |
Tongue ulceration | 19.08 | 12.72 | 21 | 61077 | 3059 | 50540967 |
Crepitations | 19.07 | 12.72 | 30 | 61068 | 6189 | 50537837 |
Red blood cell sedimentation rate increased | 18.85 | 12.72 | 6 | 61092 | 29410 | 50514616 |
Rhabdomyolysis | 18.72 | 12.72 | 12 | 61086 | 39015 | 50505011 |
Metastases to meninges | 18.58 | 12.72 | 17 | 61081 | 1985 | 50542041 |
Cerebral ventricle collapse | 18.50 | 12.72 | 5 | 61093 | 33 | 50543993 |
Aspartate aminotransferase increased | 18.49 | 12.72 | 159 | 60939 | 77839 | 50466187 |
Invasive lobular breast carcinoma | 18.44 | 12.72 | 11 | 61087 | 664 | 50543362 |
International normalised ratio increased | 18.43 | 12.72 | 15 | 61083 | 43137 | 50500889 |
Wrong technique in product usage process | 18.39 | 12.72 | 24 | 61074 | 55486 | 50488540 |
Sedation | 18.32 | 12.72 | 7 | 61091 | 30603 | 50513423 |
Lymphangioleiomyomatosis | 18.07 | 12.72 | 7 | 61091 | 159 | 50543867 |
No adverse event | 18.00 | 12.72 | 9 | 61089 | 33569 | 50510457 |
Therapeutic product effective for unapproved indication | 17.92 | 12.72 | 6 | 61092 | 88 | 50543938 |
Bowel movement irregularity | 17.88 | 12.72 | 23 | 61075 | 3945 | 50540081 |
Vein disorder | 17.86 | 12.72 | 24 | 61074 | 4295 | 50539731 |
Hepatic atrophy | 17.76 | 12.72 | 8 | 61090 | 268 | 50543758 |
Urine output decreased | 17.71 | 12.72 | 39 | 61059 | 10382 | 50533644 |
Amnesia | 17.67 | 12.72 | 15 | 61083 | 42245 | 50501781 |
Generalised oedema | 17.53 | 12.72 | 46 | 61052 | 13685 | 50530341 |
Hepatic function abnormal | 17.46 | 12.72 | 82 | 61016 | 32599 | 50511427 |
Subileus | 17.42 | 12.72 | 19 | 61079 | 2740 | 50541286 |
Hormone refractory breast cancer | 17.35 | 12.72 | 4 | 61094 | 12 | 50544014 |
Mouth injury | 17.35 | 12.72 | 11 | 61087 | 741 | 50543285 |
Congenital coronary artery malformation | 17.33 | 12.72 | 6 | 61092 | 98 | 50543928 |
Presyncope | 17.27 | 12.72 | 4 | 61094 | 24194 | 50519832 |
Febrile infection | 17.13 | 12.72 | 13 | 61085 | 1171 | 50542855 |
Anorexia nervosa | 17.09 | 12.72 | 7 | 61091 | 185 | 50543841 |
Post transplant distal limb syndrome | 17.09 | 12.72 | 7 | 61091 | 185 | 50543841 |
Metastases to stomach | 17.05 | 12.72 | 7 | 61091 | 186 | 50543840 |
Biliary dilatation | 16.89 | 12.72 | 16 | 61082 | 1953 | 50542073 |
Neutrophilic panniculitis | 16.86 | 12.72 | 5 | 61093 | 48 | 50543978 |
Transient ischaemic attack | 16.73 | 12.72 | 9 | 61089 | 32201 | 50511825 |
Abdominal pain | 16.72 | 12.72 | 388 | 60710 | 235840 | 50308186 |
Premature delivery | 16.71 | 12.72 | 4 | 61094 | 23659 | 50520367 |
Tumour pain | 16.69 | 12.72 | 13 | 61085 | 1217 | 50542809 |
Odynophagia | 16.65 | 12.72 | 29 | 61069 | 6503 | 50537523 |
Neutropenia | 16.65 | 12.72 | 261 | 60837 | 147704 | 50396322 |
Alveolar proteinosis | 16.63 | 12.72 | 8 | 61090 | 312 | 50543714 |
Injection site mass | 16.54 | 12.72 | 49 | 61049 | 15631 | 50528395 |
Device dislocation | 16.54 | 12.72 | 3 | 61095 | 21543 | 50522483 |
Taste disorder | 16.29 | 12.72 | 33 | 61065 | 8291 | 50535735 |
Toothache | 16.14 | 12.72 | 51 | 61047 | 16843 | 50527183 |
Splenic lesion | 16.14 | 12.72 | 7 | 61091 | 214 | 50543812 |
Anxiety | 16.10 | 12.72 | 137 | 60961 | 177469 | 50366557 |
Renal failure | 16.01 | 12.72 | 198 | 60900 | 106435 | 50437591 |
Bronchitis | 15.98 | 12.72 | 68 | 61030 | 104091 | 50439935 |
Incorrect dose administered | 15.97 | 12.72 | 21 | 61077 | 48393 | 50495633 |
Tinnitus | 15.92 | 12.72 | 7 | 61091 | 28125 | 50515901 |
Oral mucosal blistering | 15.86 | 12.72 | 24 | 61074 | 4788 | 50539238 |
Kidney fibrosis | 15.75 | 12.72 | 14 | 61084 | 1575 | 50542451 |
Depressed level of consciousness | 15.68 | 12.72 | 24 | 61074 | 51929 | 50492097 |
Mediastinal disorder | 15.67 | 12.72 | 8 | 61090 | 355 | 50543671 |
Dysplasia | 15.67 | 12.72 | 10 | 61088 | 681 | 50543345 |
Orthostatic hypotension | 15.66 | 12.72 | 8 | 61090 | 29473 | 50514553 |
Oedema | 15.56 | 12.72 | 141 | 60957 | 70040 | 50473986 |
Renal lymphocele | 15.49 | 12.72 | 5 | 61093 | 65 | 50543961 |
Impaired insulin secretion | 15.42 | 12.72 | 4 | 61094 | 22 | 50544004 |
Anal ulcer | 15.39 | 12.72 | 9 | 61089 | 524 | 50543502 |
Tonic convulsion | 15.37 | 12.72 | 12 | 61086 | 1127 | 50542899 |
Atrial fibrillation | 15.25 | 12.72 | 67 | 61031 | 101678 | 50442348 |
Delayed graft function | 15.23 | 12.72 | 11 | 61087 | 919 | 50543107 |
Carcinoid heart disease | 15.13 | 12.72 | 4 | 61094 | 24 | 50544002 |
Hepatic failure | 15.10 | 12.72 | 78 | 61020 | 32205 | 50511821 |
Primary pulmonary melanoma | 15.09 | 12.72 | 3 | 61095 | 3 | 50544023 |
Pleural mass | 15.09 | 12.72 | 3 | 61095 | 3 | 50544023 |
Vasoactive intestinal polypeptide increased | 15.09 | 12.72 | 3 | 61095 | 3 | 50544023 |
Ovarian cyst torsion | 15.09 | 12.72 | 3 | 61095 | 3 | 50544023 |
Sleep apnoea syndrome | 15.06 | 12.72 | 5 | 61093 | 23863 | 50520163 |
Neutrophil count decreased | 14.93 | 12.72 | 101 | 60997 | 45925 | 50498101 |
Cardiac failure congestive | 14.93 | 12.72 | 52 | 61046 | 84330 | 50459696 |
Steatorrhoea | 14.87 | 12.72 | 8 | 61090 | 396 | 50543630 |
Stevens-Johnson syndrome | 14.74 | 12.72 | 4 | 61094 | 21748 | 50522278 |
Retinal detachment | 14.71 | 12.72 | 24 | 61074 | 5105 | 50538921 |
Carbohydrate antigen 19-9 increased | 14.56 | 12.72 | 6 | 61092 | 161 | 50543865 |
Atypical pneumonia | 14.55 | 12.72 | 20 | 61078 | 3655 | 50540371 |
Basal cell carcinoma | 14.55 | 12.72 | 5 | 61093 | 23351 | 50520675 |
Metastases to breast | 14.48 | 12.72 | 7 | 61091 | 276 | 50543750 |
Noninfective gingivitis | 14.42 | 12.72 | 12 | 61086 | 1234 | 50542792 |
Uterine mass | 14.39 | 12.72 | 7 | 61091 | 280 | 50543746 |
Mucosal haemorrhage | 14.34 | 12.72 | 10 | 61088 | 790 | 50543236 |
Cytomegalovirus infection | 14.31 | 12.72 | 51 | 61047 | 17911 | 50526115 |
Gastrooesophageal reflux disease | 14.27 | 12.72 | 46 | 61052 | 76382 | 50467644 |
Product quality issue | 14.11 | 12.72 | 10 | 61088 | 30848 | 50513178 |
Peritoneal disorder | 14.09 | 12.72 | 8 | 61090 | 440 | 50543586 |
Pneumothorax | 14.00 | 12.72 | 43 | 61055 | 13991 | 50530035 |
Product prescribing error | 13.93 | 12.72 | 4 | 61094 | 20957 | 50523069 |
Carcinoid tumour | 13.92 | 12.72 | 7 | 61091 | 301 | 50543725 |
Ascariasis | 13.87 | 12.72 | 3 | 61095 | 6 | 50544020 |
Varicella zoster virus infection | 13.76 | 12.72 | 16 | 61082 | 2473 | 50541553 |
Pneumonitis chemical | 13.72 | 12.72 | 6 | 61092 | 187 | 50543839 |
Radiation pneumonitis | 13.70 | 12.72 | 12 | 61086 | 1323 | 50542703 |
Muscle spasms | 13.67 | 12.72 | 92 | 61006 | 125461 | 50418565 |
Focal segmental glomerulosclerosis | 13.66 | 12.72 | 12 | 61086 | 1329 | 50542697 |
Rash | 13.62 | 12.72 | 652 | 60446 | 436819 | 50107207 |
Dermatitis | 13.60 | 12.72 | 43 | 61055 | 14208 | 50529818 |
Skin lesion | 13.51 | 12.72 | 66 | 61032 | 26661 | 50517365 |
Upper respiratory tract infection | 13.50 | 12.72 | 38 | 61060 | 65860 | 50478166 |
Burning sensation mucosal | 13.43 | 12.72 | 4 | 61094 | 39 | 50543987 |
Perineal ulceration | 13.43 | 12.72 | 4 | 61094 | 39 | 50543987 |
Central nervous system viral infection | 13.36 | 12.72 | 5 | 61093 | 103 | 50543923 |
Joint range of motion decreased | 13.33 | 12.72 | 3 | 61095 | 18509 | 50525517 |
Intestinal obstruction | 13.22 | 12.72 | 65 | 61033 | 26318 | 50517708 |
Mental disorder | 13.21 | 12.72 | 5 | 61093 | 21986 | 50522040 |
Therapeutic product ineffective for unapproved indication | 13.18 | 12.72 | 6 | 61092 | 206 | 50543820 |
Ovarian cyst | 13.14 | 12.72 | 42 | 61056 | 13954 | 50530072 |
Oxygen saturation decreased | 13.05 | 12.72 | 45 | 61053 | 73203 | 50470823 |
Pancreatitis viral | 13.01 | 12.72 | 3 | 61095 | 9 | 50544017 |
Eosinophil cationic protein increased | 13.00 | 12.72 | 4 | 61094 | 44 | 50543982 |
Oral administration complication | 12.97 | 12.72 | 5 | 61093 | 112 | 50543914 |
Blister | 12.95 | 12.72 | 56 | 61042 | 85362 | 50458664 |
Oral disorder | 12.93 | 12.72 | 29 | 61069 | 7815 | 50536211 |
Alveolar lung disease | 12.89 | 12.72 | 5 | 61093 | 114 | 50543912 |
Breast inflammation | 12.81 | 12.72 | 5 | 61093 | 116 | 50543910 |
Portal hypertension | 12.75 | 12.72 | 18 | 61080 | 3374 | 50540652 |
Heart rate increased | 12.75 | 12.72 | 49 | 61049 | 77201 | 50466825 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Malignant neoplasm progression | 935.77 | 13.01 | 797 | 40853 | 73062 | 29459815 |
Stomatitis | 623.30 | 13.01 | 473 | 41177 | 36640 | 29496237 |
Neoplasm malignant | 320.29 | 13.01 | 232 | 41418 | 16693 | 29516184 |
Neoplasm progression | 276.83 | 13.01 | 221 | 41429 | 18391 | 29514486 |
Metastases to lung | 189.32 | 13.01 | 125 | 41525 | 7730 | 29525147 |
Metastases to liver | 185.31 | 13.01 | 145 | 41505 | 11711 | 29521166 |
Pneumonitis | 164.24 | 13.01 | 200 | 41450 | 27844 | 29505033 |
Diarrhoea | 153.69 | 13.01 | 893 | 40757 | 331805 | 29201072 |
Polyomavirus viraemia | 143.08 | 13.01 | 48 | 41602 | 601 | 29532276 |
Kidney transplant rejection | 125.60 | 13.01 | 93 | 41557 | 6912 | 29525965 |
Polyomavirus-associated nephropathy | 122.68 | 13.01 | 70 | 41580 | 3326 | 29529551 |
Interstitial lung disease | 120.49 | 13.01 | 257 | 41393 | 57461 | 29475416 |
Oral pain | 114.37 | 13.01 | 99 | 41551 | 9208 | 29523669 |
BK virus infection | 113.64 | 13.01 | 75 | 41575 | 4632 | 29528245 |
Cough | 110.97 | 13.01 | 411 | 41239 | 126316 | 29406561 |
Mouth ulceration | 107.20 | 13.01 | 100 | 41550 | 10255 | 29522622 |
Post transplant lymphoproliferative disorder | 100.90 | 13.01 | 74 | 41576 | 5419 | 29527458 |
Proteinuria | 97.87 | 13.01 | 116 | 41534 | 15688 | 29517189 |
Decreased appetite | 95.24 | 13.01 | 431 | 41219 | 144911 | 29387966 |
Death | 95.00 | 13.01 | 812 | 40838 | 341272 | 29191605 |
Viraemia | 92.53 | 13.01 | 40 | 41610 | 1034 | 29531843 |
Drug abuse | 92.07 | 13.01 | 5 | 41645 | 79878 | 29452999 |
Heart transplant rejection | 86.68 | 13.01 | 39 | 41611 | 1112 | 29531765 |
Metastases to bone | 84.49 | 13.01 | 86 | 41564 | 9812 | 29523065 |
Liver transplant rejection | 83.09 | 13.01 | 45 | 41605 | 1929 | 29530948 |
Hepatitis E | 81.34 | 13.01 | 42 | 41608 | 1632 | 29531245 |
Fatigue | 78.56 | 13.01 | 734 | 40916 | 316087 | 29216790 |
Acne | 78.50 | 13.01 | 80 | 41570 | 9140 | 29523737 |
Immunosuppressant drug level decreased | 77.05 | 13.01 | 36 | 41614 | 1122 | 29531755 |
C-reactive protein increased | 75.52 | 13.01 | 182 | 41468 | 44081 | 29488796 |
Renal impairment | 74.64 | 13.01 | 268 | 41382 | 81065 | 29451812 |
Hyperglycaemia | 74.20 | 13.01 | 155 | 41495 | 34132 | 29498745 |
Mucosal inflammation | 73.29 | 13.01 | 147 | 41503 | 31448 | 29501429 |
Transplant rejection | 66.13 | 13.01 | 73 | 41577 | 9139 | 29523738 |
Lung disorder | 64.23 | 13.01 | 136 | 41514 | 30226 | 29502651 |
Product use in unapproved indication | 63.96 | 13.01 | 267 | 41383 | 86608 | 29446269 |
Fall | 63.07 | 13.01 | 95 | 41555 | 177083 | 29355794 |
Concomitant disease progression | 62.84 | 13.01 | 40 | 41610 | 2321 | 29530556 |
Blood chromogranin A increased | 61.03 | 13.01 | 19 | 41631 | 184 | 29532693 |
Pleural effusion | 59.32 | 13.01 | 229 | 41421 | 71679 | 29461198 |
Gamma-glutamyltransferase increased | 57.99 | 13.01 | 121 | 41529 | 26616 | 29506261 |
Immunosuppressant drug level increased | 57.15 | 13.01 | 50 | 41600 | 4715 | 29528162 |
Drug ineffective | 56.94 | 13.01 | 291 | 41359 | 362879 | 29169998 |
Blood creatinine increased | 53.86 | 13.01 | 250 | 41400 | 84852 | 29448025 |
Aphthous ulcer | 51.45 | 13.01 | 44 | 41606 | 4024 | 29528853 |
Cytomegalovirus infection | 51.44 | 13.01 | 106 | 41544 | 23109 | 29509768 |
Lymphocele | 49.57 | 13.01 | 28 | 41622 | 1304 | 29531573 |
Complications of transplanted kidney | 48.45 | 13.01 | 42 | 41608 | 3912 | 29528965 |
Hypotension | 47.17 | 13.01 | 130 | 41520 | 194224 | 29338653 |
Bradycardia | 46.71 | 13.01 | 17 | 41633 | 65612 | 29467265 |
Cholangitis | 46.12 | 13.01 | 55 | 41595 | 7482 | 29525395 |
Hepatic lesion | 45.93 | 13.01 | 37 | 41613 | 3113 | 29529764 |
Atrial fibrillation | 45.48 | 13.01 | 49 | 41601 | 105597 | 29427280 |
Lung infiltration | 44.56 | 13.01 | 68 | 41582 | 11711 | 29521166 |
Myocardial infarction | 44.40 | 13.01 | 54 | 41596 | 110242 | 29422635 |
Metastases to lymph nodes | 43.91 | 13.01 | 40 | 41610 | 3977 | 29528900 |
Blood pressure increased | 43.91 | 13.01 | 213 | 41437 | 73590 | 29459287 |
Oedema peripheral | 43.57 | 13.01 | 272 | 41378 | 103285 | 29429592 |
Vascular hyalinosis | 43.47 | 13.01 | 10 | 41640 | 24 | 29532853 |
Renal transplant failure | 43.03 | 13.01 | 23 | 41627 | 960 | 29531917 |
Thrombotic microangiopathy | 43.00 | 13.01 | 57 | 41593 | 8624 | 29524253 |
Acanthoma | 42.62 | 13.01 | 10 | 41640 | 27 | 29532850 |
Renal tubular atrophy | 41.79 | 13.01 | 23 | 41627 | 1018 | 29531859 |
Pyrexia | 40.07 | 13.01 | 597 | 41053 | 287025 | 29245852 |
Epstein-Barr virus infection | 39.95 | 13.01 | 48 | 41602 | 6581 | 29526296 |
Second primary malignancy | 39.51 | 13.01 | 48 | 41602 | 6657 | 29526220 |
Bile duct stenosis | 39.47 | 13.01 | 23 | 41627 | 1137 | 29531740 |
Metastasis | 39.16 | 13.01 | 35 | 41615 | 3394 | 29529483 |
Blood pressure systolic increased | 38.60 | 13.01 | 78 | 41572 | 16767 | 29516110 |
General physical health deterioration | 37.69 | 13.01 | 261 | 41389 | 102596 | 29430281 |
Electrocardiogram QT prolonged | 36.75 | 13.01 | 4 | 41646 | 36133 | 29496744 |
Osteonecrosis of jaw | 36.12 | 13.01 | 75 | 41575 | 16435 | 29516442 |
Lymphangiosis carcinomatosa | 35.54 | 13.01 | 19 | 41631 | 793 | 29532084 |
Drug hypersensitivity | 35.05 | 13.01 | 27 | 41623 | 68379 | 29464498 |
Carcinoid crisis | 34.95 | 13.01 | 13 | 41637 | 224 | 29532653 |
Human herpesvirus 8 infection | 34.79 | 13.01 | 19 | 41631 | 828 | 29532049 |
Foetal exposure during pregnancy | 33.80 | 13.01 | 4 | 41646 | 33863 | 29499014 |
Metastases to peritoneum | 33.76 | 13.01 | 23 | 41627 | 1497 | 29531380 |
Anaemia | 33.57 | 13.01 | 431 | 41219 | 200520 | 29332357 |
Epistaxis | 33.50 | 13.01 | 153 | 41497 | 51551 | 29481326 |
Palmar-plantar erythrodysaesthesia syndrome | 33.41 | 13.01 | 68 | 41582 | 14691 | 29518186 |
Pancreatic neuroendocrine tumour metastatic | 33.38 | 13.01 | 10 | 41640 | 84 | 29532793 |
Depression | 32.89 | 13.01 | 43 | 41607 | 85104 | 29447773 |
Metastases to central nervous system | 32.55 | 13.01 | 45 | 41605 | 7086 | 29525791 |
Suicidal ideation | 32.51 | 13.01 | 5 | 41645 | 34711 | 29498166 |
Chronic allograft nephropathy | 32.38 | 13.01 | 20 | 41630 | 1100 | 29531777 |
Cardiac arrest | 32.27 | 13.01 | 44 | 41606 | 85547 | 29447330 |
Weight decreased | 32.01 | 13.01 | 339 | 41311 | 150566 | 29382311 |
Metastases to gastrointestinal tract | 31.98 | 13.01 | 9 | 41641 | 59 | 29532818 |
Dizziness | 31.91 | 13.01 | 148 | 41502 | 189536 | 29343341 |
Kidney fibrosis | 31.89 | 13.01 | 25 | 41625 | 2022 | 29530855 |
Needle issue | 31.70 | 13.01 | 36 | 41614 | 4647 | 29528230 |
Isosporiasis | 31.00 | 13.01 | 9 | 41641 | 67 | 29532810 |
International normalised ratio increased | 30.72 | 13.01 | 12 | 41638 | 44360 | 29488517 |
Loss of consciousness | 30.06 | 13.01 | 36 | 41614 | 74020 | 29458857 |
Metastases to pleura | 29.55 | 13.01 | 13 | 41637 | 351 | 29532526 |
Drug level decreased | 29.39 | 13.01 | 40 | 41610 | 6207 | 29526670 |
Agitation | 29.27 | 13.01 | 18 | 41632 | 51286 | 29481591 |
Lactic acidosis | 29.15 | 13.01 | 4 | 41646 | 30243 | 29502634 |
Hypercholesterolaemia | 29.10 | 13.01 | 43 | 41607 | 7195 | 29525682 |
Condition aggravated | 29.04 | 13.01 | 107 | 41543 | 146188 | 29386689 |
Intentional product misuse | 28.24 | 13.01 | 7 | 41643 | 34654 | 29498223 |
Neoplasm | 28.19 | 13.01 | 32 | 41618 | 4129 | 29528748 |
Paraesthesia | 27.90 | 13.01 | 21 | 41629 | 53824 | 29479053 |
Angiomyolipoma | 27.83 | 13.01 | 5 | 41645 | 0 | 29532877 |
Abdominal pain | 27.73 | 13.01 | 302 | 41348 | 135055 | 29397822 |
Tachycardia | 27.52 | 13.01 | 37 | 41613 | 72373 | 29460504 |
Somnolence | 27.38 | 13.01 | 57 | 41593 | 93898 | 29438979 |
Psoriasis | 27.26 | 13.01 | 6 | 41644 | 32221 | 29500656 |
Cardio-respiratory arrest | 27.18 | 13.01 | 19 | 41631 | 50582 | 29482295 |
Metastases to pancreas | 26.92 | 13.01 | 11 | 41639 | 246 | 29532631 |
Hallucination | 26.48 | 13.01 | 15 | 41635 | 44697 | 29488180 |
Ascites | 26.48 | 13.01 | 112 | 41538 | 36507 | 29496370 |
Anxiety | 26.41 | 13.01 | 50 | 41600 | 85315 | 29447562 |
Metastases to adrenals | 25.60 | 13.01 | 16 | 41634 | 899 | 29531978 |
Hyperhidrosis | 25.53 | 13.01 | 32 | 41618 | 64508 | 29468369 |
Squamous cell carcinoma of skin | 25.50 | 13.01 | 47 | 41603 | 9439 | 29523438 |
Disease progression | 25.50 | 13.01 | 200 | 41450 | 81716 | 29451161 |
Blood alkaline phosphatase increased | 25.49 | 13.01 | 93 | 41557 | 28313 | 29504564 |
Cardiac failure congestive | 25.36 | 13.01 | 43 | 41607 | 76538 | 29456339 |
Neuropathy peripheral | 25.30 | 13.01 | 38 | 41612 | 70989 | 29461888 |
Hypertriglyceridaemia | 25.28 | 13.01 | 41 | 41609 | 7434 | 29525443 |
Product dose omission issue | 25.22 | 13.01 | 62 | 41588 | 96321 | 29436556 |
Haemoglobin decreased | 25.13 | 13.01 | 248 | 41402 | 108127 | 29424750 |
Hypoaesthesia | 25.05 | 13.01 | 23 | 41627 | 53444 | 29479433 |
Pancreatic neuroendocrine tumour | 24.92 | 13.01 | 10 | 41640 | 213 | 29532664 |
Syncope | 24.88 | 13.01 | 48 | 41602 | 81323 | 29451554 |
Neuroendocrine tumour | 24.78 | 13.01 | 14 | 41636 | 652 | 29532225 |
Cerebrovascular accident | 24.73 | 13.01 | 44 | 41606 | 76867 | 29456010 |
Musculoskeletal stiffness | 24.53 | 13.01 | 11 | 41639 | 37447 | 29495430 |
Pseudohypoaldosteronism | 24.38 | 13.01 | 5 | 41645 | 5 | 29532872 |
Febrile neutropenia | 24.35 | 13.01 | 79 | 41571 | 112161 | 29420716 |
Human polyomavirus infection | 24.30 | 13.01 | 14 | 41636 | 677 | 29532200 |
Actinic keratosis | 23.78 | 13.01 | 28 | 41622 | 3758 | 29529119 |
Parvovirus B19 infection | 23.70 | 13.01 | 14 | 41636 | 710 | 29532167 |
Coma | 23.70 | 13.01 | 13 | 41637 | 39437 | 29493440 |
Asthma | 23.68 | 13.01 | 9 | 41641 | 33840 | 29499037 |
Overdose | 23.61 | 13.01 | 48 | 41602 | 79771 | 29453106 |
Transitional cell carcinoma metastatic | 23.58 | 13.01 | 6 | 41644 | 25 | 29532852 |
Blood gastrin increased | 23.39 | 13.01 | 6 | 41644 | 26 | 29532851 |
Neutropenia | 23.18 | 13.01 | 101 | 41549 | 131610 | 29401267 |
Dysgeusia | 22.73 | 13.01 | 77 | 41573 | 22597 | 29510280 |
Blood lactate dehydrogenase increased | 22.68 | 13.01 | 69 | 41581 | 19140 | 29513737 |
Plasma cell myeloma | 22.63 | 13.01 | 12 | 41638 | 37103 | 29495774 |
Insulinoma | 22.27 | 13.01 | 4 | 41646 | 0 | 29532877 |
COVID-19 | 22.16 | 13.01 | 105 | 41545 | 35909 | 29496968 |
Therapeutic product effect incomplete | 22.13 | 13.01 | 14 | 41636 | 39291 | 29493586 |
Anorectal varices | 22.07 | 13.01 | 6 | 41644 | 34 | 29532843 |
Hepatic artery stenosis | 21.77 | 13.01 | 8 | 41642 | 133 | 29532744 |
Superinfection viral | 21.73 | 13.01 | 5 | 41645 | 12 | 29532865 |
Cell marker increased | 21.55 | 13.01 | 11 | 41639 | 417 | 29532460 |
Granulomatous rosacea | 21.34 | 13.01 | 8 | 41642 | 141 | 29532736 |
Metastases to the mediastinum | 21.28 | 13.01 | 9 | 41641 | 220 | 29532657 |
Chronic obstructive pulmonary disease | 21.18 | 13.01 | 16 | 41634 | 40939 | 29491938 |
Rash | 21.13 | 13.01 | 380 | 41270 | 189439 | 29343438 |
Renal cancer metastatic | 20.62 | 13.01 | 11 | 41639 | 457 | 29532420 |
Metastases to spine | 20.59 | 13.01 | 20 | 41630 | 2156 | 29530721 |
COVID-19 pneumonia | 20.52 | 13.01 | 43 | 41607 | 9479 | 29523398 |
Donor specific antibody present | 20.48 | 13.01 | 7 | 41643 | 93 | 29532784 |
Dyslipidaemia | 20.17 | 13.01 | 33 | 41617 | 6028 | 29526849 |
Crepitations | 20.17 | 13.01 | 22 | 41628 | 2717 | 29530160 |
Complications of transplanted heart | 20.12 | 13.01 | 9 | 41641 | 253 | 29532624 |
Biliary anastomosis complication | 19.96 | 13.01 | 7 | 41643 | 101 | 29532776 |
Anaphylactic reaction | 19.85 | 13.01 | 7 | 41643 | 27566 | 29505311 |
Treatment noncompliance | 19.53 | 13.01 | 5 | 41645 | 24222 | 29508655 |
Dehydration | 19.48 | 13.01 | 247 | 41403 | 114501 | 29418376 |
Body temperature decreased | 19.41 | 13.01 | 45 | 41605 | 10619 | 29522258 |
Muscle spasms | 19.36 | 13.01 | 39 | 41611 | 65043 | 29467834 |
Blood cholesterol increased | 19.34 | 13.01 | 57 | 41593 | 15538 | 29517339 |
Polyomavirus test positive | 19.12 | 13.01 | 7 | 41643 | 115 | 29532762 |
Tumour compression | 18.85 | 13.01 | 7 | 41643 | 120 | 29532757 |
Feeding disorder | 18.26 | 13.01 | 31 | 41619 | 5836 | 29527041 |
Diabetes mellitus | 18.23 | 13.01 | 107 | 41543 | 39724 | 29493153 |
Intentional product use issue | 17.95 | 13.01 | 20 | 41630 | 42478 | 29490399 |
Bone pain | 17.92 | 13.01 | 62 | 41588 | 18390 | 29514487 |
Concomitant disease aggravated | 17.79 | 13.01 | 28 | 41622 | 4950 | 29527927 |
Off label use | 17.61 | 13.01 | 308 | 41342 | 300492 | 29232385 |
Obstructive nephropathy | 17.61 | 13.01 | 5 | 41645 | 34 | 29532843 |
Complex regional pain syndrome | 17.41 | 13.01 | 10 | 41640 | 481 | 29532396 |
Loss of personal independence in daily activities | 17.41 | 13.01 | 7 | 41643 | 25433 | 29507444 |
Gonococcal infection | 17.36 | 13.01 | 5 | 41645 | 36 | 29532841 |
Transitional cell cancer of renal pelvis and ureter metastatic | 17.27 | 13.01 | 4 | 41646 | 10 | 29532867 |
Oropharyngeal pain | 17.02 | 13.01 | 84 | 41566 | 29201 | 29503676 |
Dyspnoea | 17.01 | 13.01 | 590 | 41060 | 326142 | 29206735 |
Hepatic vein stenosis | 17.00 | 13.01 | 4 | 41646 | 11 | 29532866 |
Rhabdomyoma | 16.70 | 13.01 | 3 | 41647 | 0 | 29532877 |
Metastatic carcinoid tumour | 16.50 | 13.01 | 4 | 41646 | 13 | 29532864 |
Balance disorder | 16.43 | 13.01 | 16 | 41634 | 36154 | 29496723 |
Onychoclasis | 16.37 | 13.01 | 16 | 41634 | 1737 | 29531140 |
Coronary artery disease | 16.36 | 13.01 | 23 | 41627 | 44167 | 29488710 |
Arthropathy | 16.35 | 13.01 | 5 | 41645 | 21549 | 29511328 |
Brain neoplasm | 16.33 | 13.01 | 20 | 41630 | 2796 | 29530081 |
Bacteriuria | 16.29 | 13.01 | 8 | 41642 | 279 | 29532598 |
Contraindicated product administered | 16.28 | 13.01 | 3 | 41647 | 18263 | 29514614 |
Respiratory arrest | 16.27 | 13.01 | 8 | 41642 | 25825 | 29507052 |
Astrocytoma, low grade | 16.19 | 13.01 | 5 | 41645 | 47 | 29532830 |
Toxic epidermal necrolysis | 16.14 | 13.01 | 3 | 41647 | 18150 | 29514727 |
Oesophageal obstruction | 16.07 | 13.01 | 9 | 41641 | 412 | 29532465 |
Tumour pain | 16.05 | 13.01 | 12 | 41638 | 904 | 29531973 |
Blood triglycerides increased | 16 | 13.01 | 47 | 41603 | 12787 | 29520090 |
Eating disorder | 15.94 | 13.01 | 33 | 41617 | 7214 | 29525663 |
Unresponsive to stimuli | 15.50 | 13.01 | 8 | 41642 | 25118 | 29507759 |
Pulmonary toxicity | 15.43 | 13.01 | 26 | 41624 | 4864 | 29528013 |
Alveolitis necrotising | 15.13 | 13.01 | 4 | 41646 | 20 | 29532857 |
Procedural hypertension | 15.02 | 13.01 | 5 | 41645 | 61 | 29532816 |
Productive cough | 14.97 | 13.01 | 85 | 41565 | 31174 | 29501703 |
Oedema | 14.96 | 13.01 | 103 | 41547 | 40380 | 29492497 |
Malaise | 14.85 | 13.01 | 311 | 41339 | 159291 | 29373586 |
Chimerism | 14.81 | 13.01 | 7 | 41643 | 224 | 29532653 |
Asthenia | 14.73 | 13.01 | 402 | 41248 | 214848 | 29318029 |
Muscular weakness | 14.64 | 13.01 | 42 | 41608 | 62010 | 29470867 |
Renal hamartoma | 14.63 | 13.01 | 3 | 41647 | 3 | 29532874 |
Prostate cancer | 14.49 | 13.01 | 9 | 41641 | 25518 | 29507359 |
Tremor | 14.43 | 13.01 | 54 | 41596 | 73484 | 29459393 |
Therapy cessation | 14.39 | 13.01 | 49 | 41601 | 14413 | 29518464 |
Hernial eventration | 14.33 | 13.01 | 5 | 41645 | 71 | 29532806 |
Orthostatic hypotension | 14.27 | 13.01 | 7 | 41643 | 22622 | 29510255 |
Acquired phimosis | 14.26 | 13.01 | 5 | 41645 | 72 | 29532805 |
Malignant ascites | 14.23 | 13.01 | 8 | 41642 | 369 | 29532508 |
Acute respiratory distress syndrome | 14.20 | 13.01 | 67 | 41583 | 22868 | 29510009 |
Subdural haematoma | 14.20 | 13.01 | 4 | 41646 | 18189 | 29514688 |
Oxygen saturation decreased | 14.17 | 13.01 | 26 | 41624 | 44911 | 29487966 |
Blood glucose increased | 14.15 | 13.01 | 136 | 41514 | 58848 | 29474029 |
Dysphonia | 14.09 | 13.01 | 59 | 41591 | 19137 | 29513740 |
Oligoarthritis | 14.08 | 13.01 | 5 | 41645 | 75 | 29532802 |
Hepatic neoplasm | 13.96 | 13.01 | 15 | 41635 | 1821 | 29531056 |
Metastases to eye | 13.96 | 13.01 | 5 | 41645 | 77 | 29532800 |
Drug withdrawal syndrome | 13.95 | 13.01 | 4 | 41646 | 17980 | 29514897 |
Oral discomfort | 13.88 | 13.01 | 17 | 41633 | 2376 | 29530501 |
Insomnia | 13.88 | 13.01 | 71 | 41579 | 88690 | 29444187 |
Incisional hernia | 13.87 | 13.01 | 12 | 41638 | 1114 | 29531763 |
Unevaluable event | 13.79 | 13.01 | 13 | 41637 | 29838 | 29503039 |
Bile output abnormal | 13.75 | 13.01 | 4 | 41646 | 30 | 29532847 |
Restlessness | 13.74 | 13.01 | 7 | 41643 | 22138 | 29510739 |
Dysarthria | 13.66 | 13.01 | 14 | 41636 | 30897 | 29501980 |
Metastases to pelvis | 13.65 | 13.01 | 7 | 41643 | 268 | 29532609 |
Tumour associated fever | 13.63 | 13.01 | 7 | 41643 | 269 | 29532608 |
Cardiogenic shock | 13.60 | 13.01 | 5 | 41645 | 19185 | 29513692 |
Renal cell carcinoma | 13.55 | 13.01 | 24 | 41626 | 4672 | 29528205 |
Metastases to kidney | 13.41 | 13.01 | 7 | 41643 | 278 | 29532599 |
Peritoneal lesion | 13.41 | 13.01 | 3 | 41647 | 6 | 29532871 |
Croup infectious | 13.39 | 13.01 | 7 | 41643 | 279 | 29532598 |
Premature baby | 13.12 | 13.01 | 4 | 41646 | 17276 | 29515601 |
Dermatosis | 13.10 | 13.01 | 7 | 41643 | 292 | 29532585 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Malignant neoplasm progression | 2540.11 | 12.65 | 1596 | 73234 | 111275 | 64312627 |
Stomatitis | 1337.91 | 12.65 | 1068 | 73762 | 108537 | 64315365 |
Metastases to liver | 840.64 | 12.65 | 453 | 74377 | 23488 | 64400414 |
Metastases to bone | 803.39 | 12.65 | 417 | 74413 | 20018 | 64403884 |
Pneumonitis | 497.63 | 12.65 | 435 | 74395 | 49930 | 64373972 |
Metastases to lung | 459.31 | 12.65 | 261 | 74569 | 15003 | 64408899 |
Neoplasm progression | 405.00 | 12.65 | 354 | 74476 | 40610 | 64383292 |
Mucosal inflammation | 295.97 | 12.65 | 364 | 74466 | 62220 | 64361682 |
Metastases to lymph nodes | 254.02 | 12.65 | 146 | 74684 | 8571 | 64415331 |
Disease progression | 253.41 | 12.65 | 528 | 74302 | 141152 | 64282750 |
BK virus infection | 250.97 | 12.65 | 137 | 74693 | 7275 | 64416627 |
Interstitial lung disease | 243.99 | 12.65 | 420 | 74410 | 97312 | 64326590 |
Polyomavirus viraemia | 243.98 | 12.65 | 79 | 74751 | 1083 | 64422819 |
Hyperglycaemia | 225.14 | 12.65 | 314 | 74516 | 60654 | 64363248 |
Polyomavirus-associated nephropathy | 221.91 | 12.65 | 110 | 74720 | 4778 | 64419124 |
Pleural effusion | 194.73 | 12.65 | 444 | 74386 | 126115 | 64297787 |
Kidney transplant rejection | 187.11 | 12.65 | 124 | 74706 | 9387 | 64414515 |
Tumour marker increased | 184.92 | 12.65 | 87 | 74743 | 3363 | 64420539 |
Aphthous ulcer | 181.35 | 12.65 | 137 | 74693 | 12769 | 64411133 |
Cough | 178.23 | 12.65 | 758 | 74072 | 301390 | 64122512 |
Post transplant lymphoproliferative disorder | 174.73 | 12.65 | 119 | 74711 | 9425 | 64414477 |
Mouth ulceration | 165.21 | 12.65 | 196 | 74634 | 32248 | 64391654 |
Osteonecrosis of jaw | 165.06 | 12.65 | 217 | 74613 | 39608 | 64384294 |
Transplant rejection | 157.25 | 12.65 | 143 | 74687 | 17258 | 64406644 |
Death | 152.42 | 12.65 | 1019 | 73811 | 481686 | 63942216 |
Decreased appetite | 147.88 | 12.65 | 682 | 74148 | 280607 | 64143295 |
Infusion related reaction | 143.10 | 12.65 | 13 | 74817 | 164454 | 64259448 |
Hepatic lesion | 139.57 | 12.65 | 86 | 74744 | 5738 | 64418164 |
Viraemia | 134.47 | 12.65 | 62 | 74768 | 2287 | 64421615 |
Renal impairment | 133.92 | 12.65 | 402 | 74428 | 134615 | 64289287 |
Drug abuse | 128.27 | 12.65 | 6 | 74824 | 132368 | 64291534 |
Thrombotic microangiopathy | 125.91 | 12.65 | 124 | 74706 | 16531 | 64407371 |
Lung disorder | 122.44 | 12.65 | 238 | 74592 | 60462 | 64363440 |
Fall | 122.40 | 12.65 | 184 | 74646 | 416642 | 64007260 |
Immunosuppressant drug level increased | 122.29 | 12.65 | 86 | 74744 | 7173 | 64416729 |
Drug ineffective | 120.75 | 12.65 | 534 | 74296 | 839713 | 63584189 |
Metastases to skin | 114.48 | 12.65 | 48 | 74782 | 1404 | 64422498 |
Product use in unapproved indication | 113.30 | 12.65 | 455 | 74375 | 176163 | 64247739 |
Ascites | 109.44 | 12.65 | 230 | 74600 | 61771 | 64362131 |
Neoplasm malignant | 109.29 | 12.65 | 139 | 74691 | 24549 | 64399353 |
Immunosuppressant drug level decreased | 107.33 | 12.65 | 49 | 74781 | 1766 | 64422136 |
Acne | 105.42 | 12.65 | 132 | 74698 | 22949 | 64400953 |
Proteinuria | 104.10 | 12.65 | 144 | 74686 | 27579 | 64396323 |
Arthropathy | 104.04 | 12.65 | 10 | 74820 | 120957 | 64302945 |
Musculoskeletal stiffness | 103.85 | 12.65 | 11 | 74819 | 123195 | 64300707 |
Oedema peripheral | 102.44 | 12.65 | 499 | 74331 | 209818 | 64214084 |
Condition aggravated | 102.10 | 12.65 | 172 | 74658 | 372254 | 64051648 |
Diarrhoea | 100.85 | 12.65 | 1279 | 73551 | 721425 | 63702477 |
Oral pain | 100.54 | 12.65 | 141 | 74689 | 27352 | 64396550 |
Therapeutic product effect decreased | 97.99 | 12.65 | 10 | 74820 | 115341 | 64308561 |
Hypotension | 94.58 | 12.65 | 187 | 74643 | 380787 | 64043115 |
Synovitis | 94.37 | 12.65 | 5 | 74825 | 99085 | 64324817 |
Breast cancer metastatic | 93.91 | 12.65 | 73 | 74757 | 7096 | 64416806 |
Pyrexia | 93.44 | 12.65 | 1024 | 73806 | 557620 | 63866282 |
Lymphangiosis carcinomatosa | 91.72 | 12.65 | 44 | 74786 | 1777 | 64422125 |
Needle issue | 91.31 | 12.65 | 80 | 74750 | 9192 | 64414710 |
Metastasis | 90.24 | 12.65 | 65 | 74765 | 5630 | 64418272 |
Heart transplant rejection | 89.75 | 12.65 | 39 | 74791 | 1248 | 64422654 |
Second primary malignancy | 84.36 | 12.65 | 87 | 74743 | 12250 | 64411652 |
Liver transplant rejection | 84.10 | 12.65 | 49 | 74781 | 2950 | 64420952 |
Metastases to peritoneum | 81.51 | 12.65 | 51 | 74779 | 3496 | 64420406 |
Metastases to pleura | 80.70 | 12.65 | 36 | 74794 | 1228 | 64422674 |
Blood chromogranin A increased | 80.12 | 12.65 | 26 | 74804 | 359 | 64423543 |
Infusion site coldness | 80.07 | 12.65 | 23 | 74807 | 204 | 64423698 |
Drug hypersensitivity | 79.84 | 12.65 | 95 | 74735 | 237720 | 64186182 |
Complications of transplanted kidney | 79.25 | 12.65 | 59 | 74771 | 5376 | 64418526 |
Bradycardia | 78.74 | 12.65 | 20 | 74810 | 118199 | 64305703 |
Lymphocele | 77.67 | 12.65 | 38 | 74792 | 1603 | 64422299 |
Exposure during pregnancy | 76.96 | 12.65 | 3 | 74827 | 77672 | 64346230 |
Lung infiltration | 74.70 | 12.65 | 106 | 74724 | 20783 | 64403119 |
Cytomegalovirus infection | 73.95 | 12.65 | 145 | 74685 | 37054 | 64386848 |
Gamma-glutamyltransferase decreased | 73.65 | 12.65 | 24 | 74806 | 336 | 64423566 |
Blood creatinine increased | 71.02 | 12.65 | 329 | 74501 | 135453 | 64288449 |
Bone pain | 70.97 | 12.65 | 165 | 74665 | 47407 | 64376495 |
Cell marker increased | 70.69 | 12.65 | 27 | 74803 | 615 | 64423287 |
Gamma-glutamyltransferase increased | 68.83 | 12.65 | 165 | 74665 | 48345 | 64375557 |
Somnolence | 68.72 | 12.65 | 81 | 74749 | 203564 | 64220338 |
PIK3CA-activated mutation | 68.48 | 12.65 | 25 | 74805 | 500 | 64423402 |
Blood triglycerides increased | 67.85 | 12.65 | 96 | 74734 | 18770 | 64405132 |
Systemic lupus erythematosus | 67.84 | 12.65 | 6 | 74824 | 77606 | 64346296 |
Hypertriglyceridaemia | 67.72 | 12.65 | 74 | 74756 | 11131 | 64412771 |
Weight decreased | 67.05 | 12.65 | 563 | 74267 | 285176 | 64138726 |
General physical health deterioration | 66.90 | 12.65 | 436 | 74394 | 203989 | 64219913 |
Body temperature decreased | 66.68 | 12.65 | 113 | 74717 | 25815 | 64398087 |
Pancreatic neuroendocrine tumour | 66.50 | 12.65 | 24 | 74806 | 464 | 64423438 |
Suicide attempt | 66.32 | 12.65 | 4 | 74826 | 71003 | 64352899 |
Therapy cessation | 66.24 | 12.65 | 128 | 74702 | 32361 | 64391541 |
Renal transplant failure | 65.94 | 12.65 | 34 | 74796 | 1606 | 64422296 |
Metastases to central nervous system | 65.83 | 12.65 | 81 | 74749 | 13831 | 64410071 |
Metastases to spine | 65.68 | 12.65 | 45 | 74785 | 3598 | 64420304 |
Parvovirus B19 infection | 65.65 | 12.65 | 31 | 74799 | 1208 | 64422694 |
Dysgeusia | 64.59 | 12.65 | 158 | 74672 | 46889 | 64377013 |
Drug level decreased | 64.42 | 12.65 | 73 | 74757 | 11430 | 64412472 |
Epistaxis | 63.81 | 12.65 | 254 | 74576 | 97877 | 64326025 |
Blood cholesterol increased | 63.35 | 12.65 | 163 | 74667 | 49903 | 64373999 |
Hypersensitivity | 61.22 | 12.65 | 83 | 74747 | 196369 | 64227533 |
Blood lactate dehydrogenase increased | 59.86 | 12.65 | 124 | 74706 | 32954 | 64390948 |
Carbohydrate antigen 15-3 increased | 59.48 | 12.65 | 27 | 74803 | 960 | 64422942 |
Blood glucose increased | 59.13 | 12.65 | 248 | 74582 | 97825 | 64326077 |
Diabetes mellitus | 58.52 | 12.65 | 190 | 74640 | 66284 | 64357618 |
Bone lesion | 58.11 | 12.65 | 48 | 74782 | 5089 | 64418813 |
Anaemia | 57.21 | 12.65 | 681 | 74149 | 377999 | 64045903 |
Intentional product misuse | 57.11 | 12.65 | 8 | 74822 | 72287 | 64351615 |
Pancreatic neuroendocrine tumour metastatic | 57.04 | 12.65 | 15 | 74815 | 92 | 64423810 |
Maternal exposure during pregnancy | 56.98 | 12.65 | 20 | 74810 | 95864 | 64328038 |
Hypercholesterolaemia | 56.43 | 12.65 | 79 | 74751 | 15294 | 64408608 |
Joint swelling | 55.74 | 12.65 | 103 | 74727 | 215279 | 64208623 |
Cardiac arrest | 55.56 | 12.65 | 58 | 74772 | 154006 | 64269896 |
Kidney fibrosis | 55.18 | 12.65 | 38 | 74792 | 3063 | 64420839 |
Atrial fibrillation | 53.59 | 12.65 | 72 | 74758 | 171017 | 64252885 |
Hepatitis E | 53.47 | 12.65 | 34 | 74796 | 2397 | 64421505 |
Blood pressure systolic increased | 52.55 | 12.65 | 151 | 74679 | 49302 | 64374600 |
Eating disorder | 52.46 | 12.65 | 80 | 74750 | 16725 | 64407177 |
Product dose omission issue | 52.31 | 12.65 | 91 | 74739 | 194656 | 64229246 |
Nail disorder | 52.20 | 12.65 | 57 | 74773 | 8567 | 64415335 |
Therapeutic product effect incomplete | 51.35 | 12.65 | 28 | 74802 | 103454 | 64320448 |
Drug reaction with eosinophilia and systemic symptoms | 50.80 | 12.65 | 3 | 74827 | 54214 | 64369688 |
Loss of personal independence in daily activities | 50.73 | 12.65 | 11 | 74819 | 72443 | 64351459 |
Hypophosphataemia | 50.14 | 12.65 | 73 | 74757 | 14647 | 64409255 |
Vascular hyalinosis | 50.05 | 12.65 | 11 | 74819 | 26 | 64423876 |
Neuroendocrine tumour | 49.79 | 12.65 | 25 | 74805 | 1116 | 64422786 |
Cardio-respiratory arrest | 49.74 | 12.65 | 26 | 74804 | 98367 | 64325535 |
Myocardial infarction | 49.72 | 12.65 | 72 | 74758 | 165749 | 64258153 |
Arthralgia | 49.22 | 12.65 | 306 | 74524 | 441954 | 63981948 |
Suicidal ideation | 48.89 | 12.65 | 9 | 74821 | 66533 | 64357369 |
International normalised ratio increased | 47.93 | 12.65 | 16 | 74814 | 79151 | 64344751 |
Infusion site induration | 47.72 | 12.65 | 22 | 74808 | 811 | 64423091 |
Lymphoedema | 47.40 | 12.65 | 58 | 74772 | 9847 | 64414055 |
Dizziness | 47.16 | 12.65 | 299 | 74531 | 429864 | 63994038 |
Epstein-Barr virus infection | 47.07 | 12.65 | 65 | 74765 | 12423 | 64411479 |
Metastases to the mediastinum | 46.66 | 12.65 | 19 | 74811 | 515 | 64423387 |
Concomitant disease progression | 46.58 | 12.65 | 35 | 74795 | 3234 | 64420668 |
Renal tubular atrophy | 45.59 | 12.65 | 26 | 74804 | 1503 | 64422399 |
Syncope | 44.79 | 12.65 | 71 | 74759 | 157564 | 64266338 |
Depression | 44.51 | 12.65 | 91 | 74739 | 183200 | 64240702 |
Dyslipidaemia | 44.03 | 12.65 | 54 | 74776 | 9188 | 64414714 |
Cerebrovascular accident | 44.00 | 12.65 | 57 | 74773 | 137526 | 64286376 |
Hepatic neoplasm | 43.97 | 12.65 | 33 | 74797 | 3044 | 64420858 |
Overdose | 43.35 | 12.65 | 74 | 74756 | 159492 | 64264410 |
Fatigue | 42.99 | 12.65 | 1154 | 73676 | 747576 | 63676326 |
Pericarditis | 42.74 | 12.65 | 10 | 74820 | 62506 | 64361396 |
Feeding disorder | 42.35 | 12.65 | 63 | 74767 | 12886 | 64411016 |
Acanthoma | 42.17 | 12.65 | 10 | 74820 | 37 | 64423865 |
Concomitant disease aggravated | 41.90 | 12.65 | 59 | 74771 | 11483 | 64412419 |
Lactic acidosis | 41.64 | 12.65 | 10 | 74820 | 61400 | 64362502 |
Anaphylactic reaction | 41.35 | 12.65 | 14 | 74816 | 68650 | 64355252 |
Arthritis | 41.12 | 12.65 | 23 | 74807 | 83791 | 64340111 |
Palmar-plantar erythrodysaesthesia syndrome | 40.85 | 12.65 | 98 | 74732 | 28721 | 64395181 |
Weight increased | 40.75 | 12.65 | 120 | 74710 | 213228 | 64210674 |
Hyperhidrosis | 40.72 | 12.65 | 51 | 74779 | 124869 | 64299033 |
Pneumocystis jirovecii pneumonia | 40.28 | 12.65 | 95 | 74735 | 27539 | 64396363 |
Neoplasm | 40.02 | 12.65 | 45 | 74785 | 6986 | 64416916 |
Drug level increased | 39.86 | 12.65 | 108 | 74722 | 34088 | 64389814 |
Agitation | 39.54 | 12.65 | 27 | 74803 | 88340 | 64335562 |
Chronic obstructive pulmonary disease | 38.62 | 12.65 | 17 | 74813 | 71031 | 64352871 |
Loss of consciousness | 38.32 | 12.65 | 71 | 74759 | 148294 | 64275608 |
Device related thrombosis | 38.17 | 12.65 | 26 | 74804 | 2059 | 64421843 |
Confusional state | 37.83 | 12.65 | 165 | 74665 | 260979 | 64162923 |
Toxicity to various agents | 37.63 | 12.65 | 257 | 74573 | 363256 | 64060646 |
Mean cell haemoglobin decreased | 37.48 | 12.65 | 34 | 74796 | 4088 | 64419814 |
Balance disorder | 37.07 | 12.65 | 26 | 74804 | 83900 | 64340002 |
C-reactive protein increased | 37.06 | 12.65 | 212 | 74618 | 94697 | 64329205 |
Blood alkaline phosphatase increased | 36.83 | 12.65 | 146 | 74684 | 56133 | 64367769 |
Human herpesvirus 8 infection | 36.78 | 12.65 | 20 | 74810 | 1053 | 64422849 |
Intentional product use issue | 36.56 | 12.65 | 34 | 74796 | 95330 | 64328572 |
Thrombocytopenia | 36.19 | 12.65 | 408 | 74422 | 223393 | 64200509 |
Mobility decreased | 36.10 | 12.65 | 28 | 74802 | 85812 | 64338090 |
Cholangitis | 35.97 | 12.65 | 53 | 74777 | 10749 | 64413153 |
Granulomatous rosacea | 35.06 | 12.65 | 12 | 74818 | 197 | 64423705 |
Sinusitis | 34.96 | 12.65 | 73 | 74757 | 145855 | 64278047 |
Human polyomavirus infection | 34.95 | 12.65 | 19 | 74811 | 1000 | 64422902 |
Insulinoma | 34.78 | 12.65 | 10 | 74820 | 89 | 64423813 |
Wound | 34.70 | 12.65 | 23 | 74807 | 76454 | 64347448 |
Metastases to chest wall | 34.47 | 12.65 | 14 | 74816 | 377 | 64423525 |
Serotonin syndrome | 34.42 | 12.65 | 3 | 74827 | 39279 | 64384623 |
Crepitations | 34.13 | 12.65 | 44 | 74786 | 7871 | 64416031 |
Metastases to pelvis | 33.32 | 12.65 | 15 | 74815 | 523 | 64423379 |
Cachexia | 33.29 | 12.65 | 47 | 74783 | 9170 | 64414732 |
Post-traumatic neck syndrome | 33.12 | 12.65 | 23 | 74807 | 1879 | 64422023 |
Dry skin | 32.89 | 12.65 | 132 | 74698 | 51029 | 64372873 |
Hallucination | 32.88 | 12.65 | 22 | 74808 | 72766 | 64351136 |
Metastases to thorax | 32.76 | 12.65 | 11 | 74819 | 170 | 64423732 |
Oxygen saturation decreased | 32.64 | 12.65 | 46 | 74784 | 107130 | 64316772 |
Cardiac failure congestive | 32.40 | 12.65 | 64 | 74766 | 130516 | 64293386 |
Irritable bowel syndrome | 32.35 | 12.65 | 3 | 74827 | 37366 | 64386536 |
Toxic epidermal necrolysis | 32.13 | 12.65 | 3 | 74827 | 37163 | 64386739 |
Accidental exposure to product packaging | 32.13 | 12.65 | 6 | 74824 | 3 | 64423899 |
Respiratory arrest | 31.56 | 12.65 | 11 | 74819 | 52974 | 64370928 |
Rash | 31.35 | 12.65 | 724 | 74106 | 457825 | 63966077 |
Depressed level of consciousness | 31.26 | 12.65 | 29 | 74801 | 81407 | 64342495 |
West Nile viral infection | 31.18 | 12.65 | 17 | 74813 | 900 | 64423002 |
Actinic keratosis | 31.02 | 12.65 | 34 | 74796 | 5131 | 64418771 |
Polyomavirus test positive | 30.90 | 12.65 | 11 | 74819 | 204 | 64423698 |
Injection site reaction | 30.86 | 12.65 | 8 | 74822 | 46656 | 64377246 |
Abdominal lymphadenopathy | 30.53 | 12.65 | 18 | 74812 | 1108 | 64422794 |
Asthenia | 30.24 | 12.65 | 679 | 74151 | 427365 | 63996537 |
Complications of transplanted heart | 30.19 | 12.65 | 12 | 74818 | 305 | 64423597 |
Hormone receptor positive breast cancer | 30.15 | 12.65 | 12 | 74818 | 306 | 64423596 |
Renal tubular necrosis | 30.07 | 12.65 | 74 | 74756 | 22036 | 64401866 |
Metastases to muscle | 29.87 | 12.65 | 12 | 74818 | 314 | 64423588 |
Bile duct stenosis | 29.73 | 12.65 | 21 | 74809 | 1763 | 64422139 |
Treatment noncompliance | 29.63 | 12.65 | 7 | 74823 | 43475 | 64380427 |
Vasodilatation | 29.63 | 12.65 | 26 | 74804 | 2992 | 64420910 |
Carcinoid crisis | 29.21 | 12.65 | 13 | 74817 | 441 | 64423461 |
Pericardial effusion | 29.12 | 12.65 | 106 | 74724 | 39148 | 64384754 |
Isosporiasis | 28.73 | 12.65 | 9 | 74821 | 110 | 64423792 |
Renal lymphocele | 28.59 | 12.65 | 9 | 74821 | 112 | 64423790 |
Spinal pain | 28.55 | 12.65 | 52 | 74778 | 12569 | 64411333 |
Abdominal distension | 28.51 | 12.65 | 200 | 74630 | 95794 | 64328108 |
Oncologic complication | 28.26 | 12.65 | 11 | 74819 | 264 | 64423638 |
Impaired insulin secretion | 28.16 | 12.65 | 7 | 74823 | 33 | 64423869 |
Psoriasis | 28.16 | 12.65 | 25 | 74805 | 71678 | 64352224 |
Therapy change | 28.11 | 12.65 | 36 | 74794 | 6398 | 64417504 |
Injection site pruritus | 28.03 | 12.65 | 5 | 74825 | 37821 | 64386081 |
Tachycardia | 27.92 | 12.65 | 85 | 74745 | 149494 | 64274408 |
Chronic allograft nephropathy | 27.92 | 12.65 | 19 | 74811 | 1502 | 64422400 |
Pseudocirrhosis | 27.76 | 12.65 | 14 | 74816 | 631 | 64423271 |
COVID-19 pneumonia | 27.69 | 12.65 | 60 | 74770 | 16444 | 64407458 |
Treatment failure | 27.50 | 12.65 | 59 | 74771 | 116757 | 64307145 |
Unresponsive to stimuli | 27.48 | 12.65 | 12 | 74818 | 50381 | 64373521 |
Infusion site haemorrhage | 26.96 | 12.65 | 22 | 74808 | 2293 | 64421609 |
Haemoglobin decreased | 26.87 | 12.65 | 345 | 74485 | 194718 | 64229184 |
Oral herpes | 26.86 | 12.65 | 71 | 74759 | 22081 | 64401821 |
Cheilitis | 26.84 | 12.65 | 30 | 74800 | 4626 | 64419276 |
Hepatic mass | 26.46 | 12.65 | 21 | 74809 | 2103 | 64421799 |
Platelet count decreased | 26.30 | 12.65 | 304 | 74526 | 167407 | 64256495 |
Focal segmental glomerulosclerosis | 26.21 | 12.65 | 24 | 74806 | 2920 | 64420982 |
Carcinoid heart disease | 26.08 | 12.65 | 7 | 74823 | 47 | 64423855 |
Headache | 26.01 | 12.65 | 445 | 74385 | 529022 | 63894880 |
Tumour pain | 26.01 | 12.65 | 20 | 74810 | 1913 | 64421989 |
Biliary anastomosis complication | 25.95 | 12.65 | 9 | 74821 | 154 | 64423748 |
Lymphadenopathy mediastinal | 25.90 | 12.65 | 27 | 74803 | 3849 | 64420053 |
Sedation | 25.76 | 12.65 | 8 | 74822 | 41454 | 64382448 |
Electrocardiogram QT prolonged | 25.30 | 12.65 | 33 | 74797 | 79415 | 64344487 |
Metastases to pancreas | 25.14 | 12.65 | 12 | 74818 | 479 | 64423423 |
Skin sensitisation | 24.92 | 12.65 | 14 | 74816 | 786 | 64423116 |
Breast cancer recurrent | 24.86 | 12.65 | 22 | 74808 | 2561 | 64421341 |
Anaphylactic shock | 24.81 | 12.65 | 3 | 74827 | 30325 | 64393577 |
Transitional cell carcinoma metastatic | 24.74 | 12.65 | 6 | 74824 | 25 | 64423877 |
Reflux gastritis | 24.55 | 12.65 | 15 | 74815 | 985 | 64422917 |
Unevaluable event | 24.55 | 12.65 | 14 | 74816 | 50475 | 64373427 |
Sleep apnoea syndrome | 24.28 | 12.65 | 3 | 74827 | 29829 | 64394073 |
Pulmonary mass | 24.23 | 12.65 | 72 | 74758 | 23944 | 64399958 |
Metastases to gastrointestinal tract | 24.17 | 12.65 | 8 | 74822 | 118 | 64423784 |
Orthostatic hypotension | 24.14 | 12.65 | 12 | 74818 | 46726 | 64377176 |
Cancer pain | 23.81 | 12.65 | 27 | 74803 | 4230 | 64419672 |
Osteoarthritis | 23.78 | 12.65 | 23 | 74807 | 63313 | 64360589 |
Tumour necrosis | 23.69 | 12.65 | 18 | 74812 | 1691 | 64422211 |
Plasma cell myeloma | 23.54 | 12.65 | 12 | 74818 | 46063 | 64377839 |
Drug withdrawal syndrome | 23.49 | 12.65 | 4 | 74826 | 31287 | 64392615 |
Discomfort | 23.37 | 12.65 | 36 | 74794 | 80842 | 64343060 |
Anorectal varices | 23.22 | 12.65 | 6 | 74824 | 34 | 64423868 |
Memory impairment | 23.02 | 12.65 | 40 | 74790 | 85642 | 64338260 |
Glomerular filtration rate decreased | 22.99 | 12.65 | 62 | 74768 | 19510 | 64404392 |
Injection site erythema | 22.97 | 12.65 | 29 | 74801 | 70771 | 64353131 |
Lung transplant rejection | 22.94 | 12.65 | 16 | 74814 | 1316 | 64422586 |
Febrile neutropenia | 22.86 | 12.65 | 126 | 74704 | 187531 | 64236371 |
Metastases to kidney | 22.75 | 12.65 | 11 | 74819 | 452 | 64423450 |
Donor specific antibody present | 22.75 | 12.65 | 9 | 74821 | 226 | 64423676 |
Pleural neoplasm | 22.60 | 12.65 | 9 | 74821 | 230 | 64423672 |
Steatorrhoea | 22.46 | 12.65 | 13 | 74817 | 773 | 64423129 |
Stevens-Johnson syndrome | 22.40 | 12.65 | 6 | 74824 | 34243 | 64389659 |
Tumour compression | 22.34 | 12.65 | 8 | 74822 | 151 | 64423751 |
Emotional distress | 22.31 | 12.65 | 7 | 74823 | 36031 | 64387871 |
Hallucination, visual | 22.17 | 12.65 | 3 | 74827 | 27831 | 64396071 |
Lower respiratory tract infection | 22.09 | 12.65 | 48 | 74782 | 94566 | 64329336 |
Ill-defined disorder | 21.73 | 12.65 | 12 | 74818 | 44040 | 64379862 |
Metastatic carcinoid tumour | 21.65 | 12.65 | 5 | 74825 | 16 | 64423886 |
Pulmonary toxicity | 21.60 | 12.65 | 37 | 74793 | 8524 | 64415378 |
Injury | 21.41 | 12.65 | 20 | 74810 | 55972 | 64367930 |
Post transplant distal limb syndrome | 21.34 | 12.65 | 11 | 74819 | 519 | 64423383 |
Gait disturbance | 21.29 | 12.65 | 115 | 74715 | 172040 | 64251862 |
Toothache | 21.21 | 12.65 | 56 | 74774 | 17403 | 64406499 |
Biliary dilatation | 21.20 | 12.65 | 19 | 74811 | 2249 | 64421653 |
Exposed bone in jaw | 21.02 | 12.65 | 23 | 74807 | 3464 | 64420438 |
Bone cancer | 20.91 | 12.65 | 16 | 74814 | 1519 | 64422383 |
Squamous cell carcinoma of skin | 20.87 | 12.65 | 44 | 74786 | 11832 | 64412070 |
Asthma | 20.86 | 12.65 | 50 | 74780 | 95175 | 64328727 |
Off label use | 20.86 | 12.65 | 567 | 74263 | 632239 | 63791663 |
Coma | 20.83 | 12.65 | 44 | 74786 | 87571 | 64336331 |
Lymphocyte count decreased | 20.79 | 12.65 | 98 | 74732 | 40601 | 64383301 |
Epstein-Barr viraemia | 20.76 | 12.65 | 17 | 74813 | 1780 | 64422122 |
Urticaria | 20.75 | 12.65 | 94 | 74736 | 147223 | 64276679 |
Hepatic enzyme increased | 20.74 | 12.65 | 79 | 74751 | 129864 | 64294038 |
Dysarthria | 20.69 | 12.65 | 23 | 74807 | 59383 | 64364519 |
Hyponatraemia | 20.69 | 12.65 | 95 | 74735 | 148244 | 64275658 |
Cognitive disorder | 20.69 | 12.65 | 20 | 74810 | 55067 | 64368835 |
Hypoaesthesia | 20.67 | 12.65 | 87 | 74743 | 139021 | 64284881 |
Adverse event | 20.60 | 12.65 | 10 | 74820 | 39479 | 64384423 |
Injection site mass | 20.58 | 12.65 | 55 | 74775 | 17215 | 64406687 |
Sleep disorder due to general medical condition, insomnia type | 20.53 | 12.65 | 3 | 74827 | 26267 | 64397635 |
Joint stiffness | 20.51 | 12.65 | 5 | 74825 | 30399 | 64393503 |
Tumour marker abnormal | 20.44 | 12.65 | 8 | 74822 | 195 | 64423707 |
Visual impairment | 20.43 | 12.65 | 34 | 74796 | 74043 | 64349859 |
Alveolar proteinosis | 20.41 | 12.65 | 11 | 74819 | 569 | 64423333 |
Vasoactive intestinal polypeptide increased | 20.27 | 12.65 | 4 | 74826 | 4 | 64423898 |
Carcinoembryonic antigen increased | 20.15 | 12.65 | 17 | 74813 | 1856 | 64422046 |
Pseudohypoaldosteronism | 20.04 | 12.65 | 5 | 74825 | 24 | 64423878 |
Amnesia | 19.97 | 12.65 | 16 | 74814 | 48253 | 64375649 |
Muscular weakness | 19.95 | 12.65 | 78 | 74752 | 127260 | 64296642 |
Oedema | 19.85 | 12.65 | 178 | 74652 | 91757 | 64332145 |
Cell death | 19.82 | 12.65 | 24 | 74806 | 4030 | 64419872 |
Congenital coronary artery malformation | 19.73 | 12.65 | 6 | 74824 | 66 | 64423836 |
Wrong technique in product usage process | 19.67 | 12.65 | 28 | 74802 | 64946 | 64358956 |
Vein disorder | 19.66 | 12.65 | 24 | 74806 | 4063 | 64419839 |
Helicobacter infection | 19.58 | 12.65 | 10 | 74820 | 38352 | 64385550 |
Red blood cell sedimentation rate increased | 19.45 | 12.65 | 6 | 74824 | 31229 | 64392673 |
Vision blurred | 19.33 | 12.65 | 48 | 74782 | 90268 | 64333634 |
Blood pressure fluctuation | 19.29 | 12.65 | 19 | 74811 | 51852 | 64372050 |
Hypophagia | 19.27 | 12.65 | 94 | 74736 | 39493 | 64384409 |
Liver abscess | 19.18 | 12.65 | 27 | 74803 | 5253 | 64418649 |
Anxiety | 19.13 | 12.65 | 147 | 74683 | 202502 | 64221400 |
Flatulence | 19.05 | 12.65 | 87 | 74743 | 35579 | 64388323 |
COVID-19 | 18.92 | 12.65 | 135 | 74695 | 65005 | 64358897 |
Insomnia | 18.91 | 12.65 | 143 | 74687 | 197693 | 64226209 |
Acute respiratory distress syndrome | 18.63 | 12.65 | 92 | 74738 | 38843 | 64385059 |
Recurrent cancer | 18.55 | 12.65 | 18 | 74812 | 2355 | 64421547 |
Abdominal pain | 18.54 | 12.65 | 484 | 74346 | 311891 | 64112011 |
Pulmonary tumour thrombotic microangiopathy | 18.41 | 12.65 | 6 | 74824 | 84 | 64423818 |
Drug intolerance | 18.39 | 12.65 | 135 | 74695 | 187857 | 64236045 |
Nephritic syndrome | 18.35 | 12.65 | 8 | 74822 | 258 | 64423644 |
Drug-induced liver injury | 18.24 | 12.65 | 17 | 74813 | 47626 | 64376276 |
Tongue oedema | 17.97 | 12.65 | 28 | 74802 | 5962 | 64417940 |
Dysplasia | 17.89 | 12.65 | 13 | 74817 | 1141 | 64422761 |
Superinfection viral | 17.86 | 12.65 | 5 | 74825 | 40 | 64423862 |
Transient ischaemic attack | 17.84 | 12.65 | 15 | 74815 | 44167 | 64379735 |
Transitional cell cancer of renal pelvis and ureter metastatic | 17.77 | 12.65 | 4 | 74826 | 11 | 64423891 |
Anorexia nervosa | 17.68 | 12.65 | 7 | 74823 | 176 | 64423726 |
Cornea verticillata | 17.56 | 12.65 | 6 | 74824 | 98 | 64423804 |
Obstructive nephropathy | 17.54 | 12.65 | 5 | 74825 | 43 | 64423859 |
Metastases to adrenals | 17.54 | 12.65 | 13 | 74817 | 1176 | 64422726 |
Onychoclasis | 17.45 | 12.65 | 24 | 74806 | 4568 | 64419334 |
Complex regional pain syndrome | 17.44 | 12.65 | 15 | 74815 | 1681 | 64422221 |
Neutropenic sepsis | 17.41 | 12.65 | 3 | 74827 | 23269 | 64400633 |
Intentional self-injury | 17.35 | 12.65 | 6 | 74824 | 29038 | 64394864 |
Gonococcal infection | 17.34 | 12.65 | 5 | 74825 | 45 | 64423857 |
Throat tightness | 17.30 | 12.65 | 3 | 74827 | 23157 | 64400745 |
Blood creatinine decreased | 17.17 | 12.65 | 30 | 74800 | 7020 | 64416882 |
Therapeutic product effective for unapproved indication | 17.13 | 12.65 | 6 | 74824 | 106 | 64423796 |
Gastric antral vascular ectasia | 17.03 | 12.65 | 11 | 74819 | 797 | 64423105 |
Angiomyolipoma | 17.01 | 12.65 | 7 | 74823 | 195 | 64423707 |
Muscle spasms | 17.00 | 12.65 | 95 | 74735 | 140928 | 64282974 |
Febrile convulsion | 16.94 | 12.65 | 11 | 74819 | 804 | 64423098 |
Hydrothorax | 16.90 | 12.65 | 13 | 74817 | 1244 | 64422658 |
Jejunal ulcer perforation | 16.82 | 12.65 | 6 | 74824 | 112 | 64423790 |
Malignant ascites | 16.79 | 12.65 | 12 | 74818 | 1026 | 64422876 |
Restlessness | 16.69 | 12.65 | 13 | 74817 | 39772 | 64384130 |
Mental disorder | 16.61 | 12.65 | 5 | 74825 | 26440 | 64397462 |
Gastrointestinal haemorrhage | 16.57 | 12.65 | 88 | 74742 | 132224 | 64291678 |
Mucosal toxicity | 16.39 | 12.65 | 9 | 74821 | 483 | 64423419 |
Therapeutic product ineffective for unapproved indication | 16.34 | 12.65 | 6 | 74824 | 122 | 64423780 |
Nephrotic syndrome | 16.30 | 12.65 | 35 | 74795 | 9532 | 64414370 |
Metastases to eye | 16.25 | 12.65 | 7 | 74823 | 219 | 64423683 |
Renal cancer metastatic | 16.07 | 12.65 | 10 | 74820 | 679 | 64423223 |
Burning sensation mucosal | 16.05 | 12.65 | 5 | 74825 | 60 | 64423842 |
Oral administration complication | 16.03 | 12.65 | 6 | 74824 | 129 | 64423773 |
Ventricular tachycardia | 15.96 | 12.65 | 10 | 74820 | 34255 | 64389647 |
Dyspnoea | 15.94 | 12.65 | 1001 | 73829 | 717673 | 63706229 |
Alveolitis necrotising | 15.90 | 12.65 | 4 | 74826 | 20 | 64423882 |
Hernial eventration | 15.83 | 12.65 | 5 | 74825 | 63 | 64423839 |
Alopecia | 15.72 | 12.65 | 120 | 74710 | 165570 | 64258332 |
Dehydration | 15.62 | 12.65 | 345 | 74485 | 216418 | 64207484 |
Withdrawal syndrome | 15.58 | 12.65 | 4 | 74826 | 23488 | 64400414 |
Tongue ulceration | 15.39 | 12.65 | 20 | 74810 | 3606 | 64420296 |
Gastrointestinal disorder | 15.33 | 12.65 | 53 | 74777 | 89656 | 64334246 |
Presyncope | 15.32 | 12.65 | 11 | 74819 | 35078 | 64388824 |
Inferior vena cava syndrome | 15.29 | 12.65 | 4 | 74826 | 24 | 64423878 |
Primary pulmonary melanoma | 15.21 | 12.65 | 3 | 74827 | 3 | 64423899 |
Rhabdomyolysis | 15.13 | 12.65 | 55 | 74775 | 91671 | 64332231 |
Palpitations | 15.12 | 12.65 | 66 | 74764 | 104422 | 64319480 |
Angina pectoris | 15.11 | 12.65 | 18 | 74812 | 45063 | 64378839 |
Panic attack | 15.04 | 12.65 | 3 | 74827 | 20950 | 64402952 |
Odynophagia | 14.99 | 12.65 | 34 | 74796 | 9607 | 64414295 |
Urinary fistula | 14.97 | 12.65 | 5 | 74825 | 76 | 64423826 |
Chimerism | 14.91 | 12.65 | 7 | 74823 | 269 | 64423633 |
Lymphadenopathy | 14.89 | 12.65 | 99 | 74731 | 46587 | 64377315 |
Hepatic atrophy | 14.84 | 12.65 | 8 | 74822 | 414 | 64423488 |
Graft loss | 14.84 | 12.65 | 11 | 74819 | 996 | 64422906 |
Angiosarcoma | 14.82 | 12.65 | 8 | 74822 | 415 | 64423487 |
Skin toxicity | 14.68 | 12.65 | 27 | 74803 | 6575 | 64417327 |
Neutrophilic panniculitis | 14.62 | 12.65 | 5 | 74825 | 82 | 64423820 |
Nephropathy toxic | 14.46 | 12.65 | 49 | 74781 | 17465 | 64406437 |
Biliary obstruction | 14.39 | 12.65 | 20 | 74810 | 3844 | 64420058 |
Urine output decreased | 14.38 | 12.65 | 47 | 74783 | 16445 | 64407457 |
Cardiogenic shock | 14.38 | 12.65 | 10 | 74820 | 32417 | 64391485 |
Adverse drug reaction | 14.35 | 12.65 | 19 | 74811 | 45445 | 64378457 |
Mental status changes | 14.30 | 12.65 | 31 | 74799 | 61131 | 64362771 |
Varicella zoster virus infection | 14.30 | 12.65 | 20 | 74810 | 3868 | 64420034 |
Shock | 14.22 | 12.65 | 14 | 74816 | 38226 | 64385676 |
Bile output abnormal | 14.18 | 12.65 | 4 | 74826 | 33 | 64423869 |
Ventricular fibrillation | 14.13 | 12.65 | 5 | 74825 | 23855 | 64400047 |
Poisoning | 14.00 | 12.65 | 4 | 74826 | 21875 | 64402027 |
Renal failure | 13.99 | 12.65 | 292 | 74538 | 181396 | 64242506 |
Ascariasis | 13.99 | 12.65 | 3 | 74827 | 6 | 64423896 |
Pyelonephritis | 13.98 | 12.65 | 48 | 74782 | 17218 | 64406684 |
Anal ulcer | 13.89 | 12.65 | 11 | 74819 | 1098 | 64422804 |
Delirium | 13.87 | 12.65 | 38 | 74792 | 69156 | 64354746 |
Coronary artery disease | 13.82 | 12.65 | 31 | 74799 | 60402 | 64363500 |
Bowel movement irregularity | 13.82 | 12.65 | 22 | 74808 | 4771 | 64419131 |
Haemolytic uraemic syndrome | 13.78 | 12.65 | 20 | 74810 | 4001 | 64419901 |
Carcinoid tumour pulmonary | 13.67 | 12.65 | 7 | 74823 | 326 | 64423576 |
Renal cell carcinoma | 13.62 | 12.65 | 25 | 74805 | 6079 | 64417823 |
Malignant pleural effusion | 13.59 | 12.65 | 17 | 74813 | 2950 | 64420952 |
Central nervous system viral infection | 13.51 | 12.65 | 5 | 74825 | 104 | 64423798 |
Dermatosis | 13.48 | 12.65 | 8 | 74822 | 498 | 64423404 |
Intestinal obstruction | 13.47 | 12.65 | 80 | 74750 | 36206 | 64387696 |
Product quality issue | 13.46 | 12.65 | 9 | 74821 | 29790 | 64394112 |
Bone neoplasm | 13.46 | 12.65 | 9 | 74821 | 691 | 64423211 |
Blood gastrin increased | 13.41 | 12.65 | 4 | 74826 | 41 | 64423861 |
Glossodynia | 13.37 | 12.65 | 35 | 74795 | 64661 | 64359241 |
Breast cancer | 13.33 | 12.65 | 68 | 74762 | 29080 | 64394822 |
Subdural haematoma | 13.33 | 12.65 | 8 | 74822 | 28046 | 64395856 |
Delayed graft function | 13.28 | 12.65 | 17 | 74813 | 3019 | 64420883 |
Bacteriuria | 13.23 | 12.65 | 10 | 74820 | 932 | 64422970 |
Myalgia | 13.18 | 12.65 | 119 | 74711 | 158498 | 64265404 |
Eosinophil cationic protein increased | 13.15 | 12.65 | 4 | 74826 | 44 | 64423858 |
Renal disorder | 13.15 | 12.65 | 78 | 74752 | 35287 | 64388615 |
Nightmare | 13.13 | 12.65 | 4 | 74826 | 20989 | 64402913 |
Pneumonia aspiration | 13.08 | 12.65 | 31 | 74799 | 59240 | 64364662 |
Ovarian cyst | 13.04 | 12.65 | 35 | 74795 | 10983 | 64412919 |
Skin laceration | 13.02 | 12.65 | 6 | 74824 | 24411 | 64399491 |
Product administration error | 12.97 | 12.65 | 8 | 74822 | 27635 | 64396267 |
Disseminated varicella zoster vaccine virus infection | 12.93 | 12.65 | 5 | 74825 | 118 | 64423784 |
Renal hamartoma | 12.93 | 12.65 | 5 | 74825 | 118 | 64423784 |
Metastases to bladder | 12.92 | 12.65 | 6 | 74824 | 225 | 64423677 |
Cerebral ventricle collapse | 12.77 | 12.65 | 5 | 74825 | 122 | 64423780 |
Premature delivery | 12.65 | 12.65 | 3 | 74827 | 18586 | 64405316 |
None
Source | Code | Description |
---|---|---|
ATC | L01EG02 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Mammalian target of rapamycin (mTOR) kinase inhibitors |
ATC | L04AA18 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Selective immunosuppressants |
FDA MoA | N0000175076 | Protein Kinase Inhibitors |
FDA PE | N0000175550 | Decreased Immunologic Activity |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D007155 | Immunologic Factors |
MeSH PA | D007166 | Immunosuppressive Agents |
FDA EPC | N0000175605 | Kinase Inhibitor |
FDA MoA | N0000175624 | mTOR Inhibitors |
FDA EPC | N0000175625 | mTOR Inhibitor Immunosuppressant |
FDA MoA | N0000182137 | Cytochrome P450 2D6 Inhibitors |
FDA MoA | N0000182141 | Cytochrome P450 3A4 Inhibitors |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:35705 | immunosuppressive agents |
CHEBI has role | CHEBI:68481 | mTOR inhibitors |
CHEBI has role | CHEBI:149553 | anticoronaviral drug |
CHEBI has role | CHEBI:176497 | geroprotectors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Tuberous sclerosis syndrome | indication | 7199000 | DOID:13515 |
Carcinoma of breast | indication | 254838004 | DOID:3459 |
Angiomyolipoma of kidney | indication | 254921004 | DOID:8411 |
Hormone receptor positive malignant neoplasm of breast | indication | 417181009 | |
Renal cell carcinoma | indication | 702391001 | DOID:4450 |
Pancreatic Neuroendocrine Tumor | indication | 717919005 | |
Prevention of Kidney Transplant Rejection | indication | ||
Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis | indication | ||
Hypercholesterolemia | contraindication | 13644009 | |
Proteinuria | contraindication | 29738008 | DOID:576 |
Hyperlipidemia | contraindication | 55822004 | DOID:1168 |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Stomatitis | contraindication | 61170000 | DOID:9637 |
Acute infectious disease | contraindication | 63171007 | |
Interstitial pneumonia | contraindication | 64667001 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Thrombotic thrombocytopenic purpura | contraindication | 78129009 | DOID:10772 |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Leukopenia | contraindication | 84828003 | DOID:615 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Thrombosis of renal artery | contraindication | 95579008 | |
Hemolytic uremic syndrome | contraindication | 111407006 | DOID:12554 |
Malignant lymphoma | contraindication | 118600007 | DOID:0060058 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Edema | contraindication | 267038008 | |
Impaired wound healing | contraindication | 271618001 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Hypertriglyceridemia | contraindication | 302870006 | |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Primary malignant neoplasm | contraindication | 372087000 | |
Pericardial effusion | contraindication | 373945007 | DOID:118 |
Ascites | contraindication | 389026000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
BK Polyomavirus Reactivation Nephropathy | contraindication | ||
Pleural Effusions | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 10.5 | acidic |
pKa2 | 13.7 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
10MG | AFINITOR | NOVARTIS | N022334 | March 30, 2009 | RX | TABLET | ORAL | 8778962 | Feb. 18, 2022 | TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED. |
2.5MG | AFINITOR | NOVARTIS | N022334 | July 9, 2010 | RX | TABLET | ORAL | 8778962 | Feb. 18, 2022 | TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED. |
5MG | AFINITOR | NOVARTIS | N022334 | March 30, 2009 | RX | TABLET | ORAL | 8778962 | Feb. 18, 2022 | TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED. |
7.5MG | AFINITOR | NOVARTIS | N022334 | March 30, 2012 | RX | TABLET | ORAL | 8778962 | Feb. 18, 2022 | TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED. |
2MG | AFINITOR DISPERZ | NOVARTIS PHARM | N203985 | Aug. 29, 2012 | RX | TABLET, FOR SUSPENSION | ORAL | 8778962 | Feb. 18, 2022 | ADJUNCTIVE TREATMENT OF PATIENTS WITH TSC-ASSOCIATED PARTIAL-ONSET SEIZURES |
2MG | AFINITOR DISPERZ | NOVARTIS PHARM | N203985 | Aug. 29, 2012 | RX | TABLET, FOR SUSPENSION | ORAL | 8778962 | Feb. 18, 2022 | TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED. |
3MG | AFINITOR DISPERZ | NOVARTIS PHARM | N203985 | Aug. 29, 2012 | RX | TABLET, FOR SUSPENSION | ORAL | 8778962 | Feb. 18, 2022 | ADJUNCTIVE TREATMENT OF PATIENTS WITH TSC-ASSOCIATED PARTIAL-ONSET SEIZURES |
3MG | AFINITOR DISPERZ | NOVARTIS PHARM | N203985 | Aug. 29, 2012 | RX | TABLET, FOR SUSPENSION | ORAL | 8778962 | Feb. 18, 2022 | TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED. |
5MG | AFINITOR DISPERZ | NOVARTIS PHARM | N203985 | Aug. 29, 2012 | RX | TABLET, FOR SUSPENSION | ORAL | 8778962 | Feb. 18, 2022 | ADJUNCTIVE TREATMENT OF PATIENTS WITH TSC-ASSOCIATED PARTIAL-ONSET SEIZURES |
5MG | AFINITOR DISPERZ | NOVARTIS PHARM | N203985 | Aug. 29, 2012 | RX | TABLET, FOR SUSPENSION | ORAL | 8778962 | Feb. 18, 2022 | TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED. |
10MG | AFINITOR | NOVARTIS | N022334 | March 30, 2009 | RX | TABLET | ORAL | 8436010 | Feb. 22, 2022 | TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE |
2.5MG | AFINITOR | NOVARTIS | N022334 | July 9, 2010 | RX | TABLET | ORAL | 8436010 | Feb. 22, 2022 | TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE |
5MG | AFINITOR | NOVARTIS | N022334 | March 30, 2009 | RX | TABLET | ORAL | 8436010 | Feb. 22, 2022 | TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE |
7.5MG | AFINITOR | NOVARTIS | N022334 | March 30, 2012 | RX | TABLET | ORAL | 8436010 | Feb. 22, 2022 | TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE |
10MG | AFINITOR | NOVARTIS | N022334 | March 30, 2009 | RX | TABLET | ORAL | 8410131 | Nov. 1, 2025 | TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB |
2.5MG | AFINITOR | NOVARTIS | N022334 | July 9, 2010 | RX | TABLET | ORAL | 8410131 | Nov. 1, 2025 | TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB |
5MG | AFINITOR | NOVARTIS | N022334 | March 30, 2009 | RX | TABLET | ORAL | 8410131 | Nov. 1, 2025 | TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB |
7.5MG | AFINITOR | NOVARTIS | N022334 | March 30, 2012 | RX | TABLET | ORAL | 8410131 | Nov. 1, 2025 | TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB |
10MG | AFINITOR | NOVARTIS | N022334 | March 30, 2009 | RX | TABLET | ORAL | 9006224 | July 1, 2028 | TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC |
2.5MG | AFINITOR | NOVARTIS | N022334 | July 9, 2010 | RX | TABLET | ORAL | 9006224 | July 1, 2028 | TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC |
5MG | AFINITOR | NOVARTIS | N022334 | March 30, 2009 | RX | TABLET | ORAL | 9006224 | July 1, 2028 | TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC |
7.5MG | AFINITOR | NOVARTIS | N022334 | March 30, 2012 | RX | TABLET | ORAL | 9006224 | July 1, 2028 | TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
10MG | AFINITOR | NOVARTIS | N022334 | March 30, 2009 | RX | TABLET | ORAL | Feb. 26, 2023 | TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL-DIFFERENTIATED, NON-FUNCTIONAL, NEUROENDOCRINE TUMORS (NET) OF GASTROINTESTINAL (GI) OR LUNG ORIGIN, (EXCLUDING PANCREATIC) WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE |
2.5MG | AFINITOR | NOVARTIS | N022334 | July 9, 2010 | RX | TABLET | ORAL | Feb. 26, 2023 | TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL-DIFFERENTIATED, NON-FUNCTIONAL, NEUROENDOCRINE TUMORS (NET) OF GASTROINTESTINAL (GI) OR LUNG ORIGIN, (EXCLUDING PANCREATIC) WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE |
5MG | AFINITOR | NOVARTIS | N022334 | March 30, 2009 | RX | TABLET | ORAL | Feb. 26, 2023 | TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL-DIFFERENTIATED, NON-FUNCTIONAL, NEUROENDOCRINE TUMORS (NET) OF GASTROINTESTINAL (GI) OR LUNG ORIGIN, (EXCLUDING PANCREATIC) WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE |
7.5MG | AFINITOR | NOVARTIS | N022334 | March 30, 2012 | RX | TABLET | ORAL | Feb. 26, 2023 | TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL-DIFFERENTIATED, NON-FUNCTIONAL, NEUROENDOCRINE TUMORS (NET) OF GASTROINTESTINAL (GI) OR LUNG ORIGIN, (EXCLUDING PANCREATIC) WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE |
2MG | AFINITOR DISPERZ | NOVARTIS PHARM | N203985 | Aug. 29, 2012 | RX | TABLET, FOR SUSPENSION | ORAL | April 10, 2025 | FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES |
3MG | AFINITOR DISPERZ | NOVARTIS PHARM | N203985 | Aug. 29, 2012 | RX | TABLET, FOR SUSPENSION | ORAL | April 10, 2025 | FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES |
5MG | AFINITOR DISPERZ | NOVARTIS PHARM | N203985 | Aug. 29, 2012 | RX | TABLET, FOR SUSPENSION | ORAL | April 10, 2025 | FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Peptidyl-prolyl cis-trans isomerase FKBP1A | Enzyme | INHIBITOR | IC50 | 8.26 | WOMBAT-PK | CHEMBL | |||
Multidrug resistance protein 1 | Transporter | WOMBAT-PK | |||||||
Serine/threonine-protein kinase mTOR | Kinase | INHIBITOR | IC50 | 8.70 | IUPHAR |
ID | Source |
---|---|
4028636 | VUID |
N0000178379 | NUI |
D02714 | KEGG_DRUG |
4028636 | VANDF |
C0541315 | UMLSCUI |
CHEBI:68478 | CHEBI |
E53 | PDB_CHEM_ID |
CHEMBL1908360 | ChEMBL_ID |
D000068338 | MESH_DESCRIPTOR_UI |
DB01590 | DRUGBANK_ID |
5889 | IUPHAR_LIGAND_ID |
7863 | INN_ID |
9HW64Q8G6G | UNII |
6442177 | PUBCHEM_CID |
141704 | RXNORM |
162489 | MMSL |
20447 | MMSL |
269938 | MMSL |
d05626 | MMSL |
010829 | NDDF |
428127005 | SNOMEDCT_US |
428698007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Everolimus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0470 | TABLET | 0.25 mg | ORAL | ANDA | 27 sections |
Everolimus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0471 | TABLET | 0.50 mg | ORAL | ANDA | 27 sections |
Everolimus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0472 | TABLET | 0.75 mg | ORAL | ANDA | 27 sections |
Everolimus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0480 | TABLET | 2.50 mg | ORAL | ANDA | 27 sections |
Everolimus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0480 | TABLET | 2.50 mg | ORAL | ANDA | 27 sections |
Everolimus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0481 | TABLET | 5 mg | ORAL | ANDA | 27 sections |
Everolimus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0481 | TABLET | 5 mg | ORAL | ANDA | 27 sections |
Everolimus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0482 | TABLET | 10 mg | ORAL | ANDA | 27 sections |
Everolimus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0482 | TABLET | 10 mg | ORAL | ANDA | 27 sections |
Everolimus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0497 | TABLET | 7.50 mg | ORAL | ANDA | 27 sections |
Everolimus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0497 | TABLET | 7.50 mg | ORAL | ANDA | 27 sections |
Everolimus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0604 | TABLET | 1 mg | ORAL | ANDA | 27 sections |
Zortress | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0414 | TABLET | 0.50 mg | ORAL | NDA | 31 sections |
Zortress | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0414 | TABLET | 0.50 mg | ORAL | NDA | 31 sections |
Zortress | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0415 | TABLET | 0.75 mg | ORAL | NDA | 31 sections |
Zortress | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0415 | TABLET | 0.75 mg | ORAL | NDA | 31 sections |
Zortress | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0417 | TABLET | 0.25 mg | ORAL | NDA | 31 sections |
Zortress | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0417 | TABLET | 0.25 mg | ORAL | NDA | 31 sections |
Zortress | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0422 | TABLET | 1 mg | ORAL | NDA | 31 sections |
Zortress | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0422 | TABLET | 1 mg | ORAL | NDA | 31 sections |
Afinitor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0566 | TABLET | 5 mg | ORAL | NDA | 33 sections |
Afinitor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0567 | TABLET | 10 mg | ORAL | NDA | 33 sections |
Afinitor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0594 | TABLET | 2.50 mg | ORAL | NDA | 33 sections |
Afinitor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0620 | TABLET | 7.50 mg | ORAL | NDA | 33 sections |
AfinitorDisperz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0626 | TABLET, FOR SUSPENSION | 2 mg | ORAL | NDA | 33 sections |
AfinitorDisperz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0627 | TABLET, FOR SUSPENSION | 3 mg | ORAL | NDA | 33 sections |
AfinitorDisperz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0628 | TABLET, FOR SUSPENSION | 5 mg | ORAL | NDA | 33 sections |
Everolimus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7766 | TABLET | 2.50 mg | ORAL | ANDA | 30 sections |
Everolimus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7767 | TABLET | 5 mg | ORAL | ANDA | 30 sections |
Everolimus | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7768 | TABLET | 7.50 mg | ORAL | ANDA | 30 sections |